<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE sequence-cwu SYSTEM "us-sequence-listing-v1_3-2020-10-08.dtd" [ ]><sequence-cwu id="SEQLST-1"><publication-reference><document-id><country>US</country><doc-number>20230000952</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><number>1</number><sequence-list-new-rules><s100><s160>68</s160></s100><s200><s210>1</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 1Val Pro Gly Gly1</s400><s200><s210>2</s210><s211>4</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 2Ile Pro Gly Gly1</s400><s200><s210>3</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220><s220><s221>misc_feature</s221><s222>(4)..(4)</s222><s223>Xaa can be any naturally occurring or      non-natural amino acid</s223></s220></s200><s400> 3Val Pro Gly Xaa Gly1               5</s400><s200><s210>4</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 4Ala Val Gly Val Pro1               5</s400><s200><s210>5</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220><s220><s221>misc_feature</s221><s222>(4)..(4)</s222><s223>Xaa can be any naturally occurring or      non-natural amino acid</s223></s220></s200><s400> 5Ile Pro Gly Xaa Gly1               5</s400><s200><s210>6</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 6Ile Pro Gly Val Gly1               5</s400><s200><s210>7</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220><s220><s221>misc_feature</s221><s222>(4)..(4)</s222><s223>Xaa can be any naturally occurring or      non-natural amino acid</s223></s220></s200><s400> 7Leu Pro Gly Xaa Gly1               5</s400><s200><s210>8</s210><s211>5</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 8Leu Pro Gly Val Gly1               5</s400><s200><s210>9</s210><s211>6</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 9Val Ala Pro Gly Val Gly1               5</s400><s200><s210>10</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 10Gly Val Gly Val Pro Gly Val Gly1               5</s400><s200><s210>11</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 11Val Pro Gly Phe Gly Val Gly Ala Gly1               5</s400><s200><s210>12</s210><s211>9</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>ELP component sequence</s223></s220></s200><s400> 12Val Pro Gly Val Gly Val Pro Gly Gly1               5</s400><s200><s210>13</s210><s211>30</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 13His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1               5                   10                  15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg            20                  25                  30</s400><s200><s210>14</s210><s211>39</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 14His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala Pro Pro Pro Ser        35</s400><s200><s210>15</s210><s211>21</s211><s212>PRT</s212><s213>Bos taurus</s213></s200><s400> 15Gly Ile Val Glu Gln Cys Cys Ala Ser Val Cys Ser Leu Tyr Gln Leu1               5                   10                  15Glu Asn Tyr Cys Asn            20</s400><s200><s210>16</s210><s211>30</s211><s212>PRT</s212><s213>Bos taurus</s213></s200><s400> 16Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu Tyr1               5                   10                  15Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Ala            20                  25                  30</s400><s200><s210>17</s210><s211>30</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 17His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1               5                   10                  15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg            20                  25                  30</s400><s200><s210>18</s210><s211>44</s211><s212>PRT</s212><s213>Unknown</s213><s220><s223>GLP-1 receptor agonist</s223></s220></s200><s400> 18His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala Pro Pro Ser Lys Lys Lys Lys Lys Lys        35                  40</s400><s200><s210>19</s210><s211>31</s211><s212>PRT</s212><s213>Unknown</s213><s220><s223>GLP-1 receptor agonist</s223></s220></s200><s400> 19His Val Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Glu1               5                   10                  15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Ile Lys Gly Arg Gly            20                  25                  30</s400><s200><s210>20</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Peptide linker sequence</s223></s220></s200><s400> 20Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg1               5                   10</s400><s200><s210>21</s210><s211>12</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Peptide linker sequence</s223></s220></s200><s400> 21Gly Ala Gly Ser Ser Ser Arg Arg Ala Pro Gln Thr1               5                   10</s400><s200><s210>22</s210><s211>8</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Non-cleavable spacer sequence</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(2)..(4)</s222><s223>Gly residue is optional</s223></s220><s220><s221>MISC_FEATURE</s221><s222>(6)..(8)</s222><s223>Ser residue is optional</s223></s220></s200><s400> 22Gly Gly Gly Gly Ser Ser Ser Ser1               5</s400><s200><s210>23</s210><s211>300</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence</s223></s220></s200><s400> 23aattaatacg actcactata ggggaattgt gagcggataa caattcccct ctagaaataa     60ttttgtttaa ctttaagaag gagatataca tatgcatggc gaaggcacct ttaccagcga    120tctgagcaaa cagatggaag aagaagcggt gcgcctgttt attgaatggc tgaaaaacgg    180cggcccgagc agcggcgcgc cgccgccgag cctcgagggc atgggtgggc cgggcgtggg    240tgttccgggc gtgggtgttc cgggtggcgg tgtgccgggc gcaggtgttc ctggtgtagg    300</s400><s200><s210>24</s210><s211>69</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence</s223></s220></s200><s400> 24Met His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu1               5                   10                  15Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro            20                  25                  30Ser Ser Gly Ala Pro Pro Pro Ser Leu Glu Gly Met Gly Gly Pro Gly        35                  40                  45Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala    50                  55                  60Gly Val Pro Gly Val65</s400><s200><s210>25</s210><s211>140</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with N-terminal Tev      cleavage site</s223></s220></s200><s400> 25tatggaaaac ctgtatttcc aacatggcga aggcaccttt accagcgatc tgagcaaaca     60gatggaagaa gaagcggtgc gcctgtttat tgaatggctg aaaaacggcg gcccgagcag    120cggcgcgccg ccgccgagcc                                                140</s400><s200><s210>26</s210><s211>46</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with N-terminal Tev      cleavage site</s223></s220></s200><s400> 26Met Glu Asn Leu Tyr Phe Gln His Gly Glu Gly Thr Phe Thr Ser Asp1               5                   10                  15Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp            20                  25                  30Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser        35                  40                  45</s400><s200><s210>27</s210><s211>155</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with N-terminal Tev      cleavage site and additional N-terminal sequence</s223></s220></s200><s400> 27tatggatatc ccaacgaccg aaaacctgta tttccaacat ggcgaaggca cctttaccag     60cgatctgagc aaacagatgg aagaagaagc ggtgcgcctg tttattgaat ggctgaaaaa    120cggcggcccg agcagcggcg cgccgccgcc gagcc                               155</s400><s200><s210>28</s210><s211>51</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with N-terminal Tev      cleavage site and additional N-terminal sequence</s223></s220></s200><s400> 28Met Asp Ile Pro Thr Thr Glu Asn Leu Tyr Phe Gln His Gly Glu Gly1               5                   10                  15Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu Ala Val Arg            20                  25                  30Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro        35                  40                  45Pro Pro Ser    50</s400><s200><s210>29</s210><s211>176</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with DsbA leader      sequence</s223></s220></s200><s400> 29tatgaaaaag atttggctgg cgctggctgg tttagtttta gcgtttagcg catcggcgca     60tggcgaaggc acctttacca gcgatctgag caaacagatg gaagaagaag cggtgcgcct    120gtttattgaa tggctgaaaa acggcggccc gagcagcggc gcgccgccgc cgagcc        176</s400><s200><s210>30</s210><s211>58</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Exendin-4/ELP sequence with DsbA leader      sequence</s223></s220></s200><s400> 30Met Lys Lys Ile Trp Leu Ala Leu Ala Gly Leu Val Leu Ala Phe Ser1               5                   10                  15Ala Ser Ala His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln            20                  25                  30Met Glu Glu Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly        35                  40                  45Gly Pro Ser Ser Gly Ala Pro Pro Pro Ser    50                  55</s400><s200><s210>31</s210><s211>400</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Insulin/ELP sequence</s223></s220></s200><s400> 31ctagaaataa ttttgtttaa ctttaagaag gagatataca tatgtttgtg aaccaacacc     60tgtgcggctc acacctggtg gaagctctct acctagtgtg cggggaacga ggcttcttct    120acacacccaa gacccgccgg gaggcagagg acctgcaggt ggggcaggtg gagctgggcg    180ggggccctgg tgcaggcagc ctgcagccct tggccctgga ggggtccctg cagaagcgtg    240gcattgtgga acaatgctgt accagcatct gctccctcta ccagctggag aactactgca    300acctcgaggg catgggtggg ccgggcgtgg gtgttccggg cgtgggtgtt ccgggtggcg    360gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg                          400</s400><s200><s210>32</s210><s211>119</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Insulin/ELP sequence</s223></s220></s200><s400> 32Met Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu1               5                   10                  15Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr Arg            20                  25                  30Arg Glu Ala Glu Asp Leu Gln Val Gly Gln Val Glu Leu Gly Gly Gly        35                  40                  45Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln    50                  55                  60Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr65                  70                  75                  80Gln Leu Glu Asn Tyr Cys Asn Leu Glu Gly Met Gly Gly Pro Gly Val                85                  90                  95Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly            100                 105                 110Val Pro Gly Val Gly Val Pro        115</s400><s200><s210>33</s210><s211>406</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 33Ala Asn Ala Phe Leu Glu Glu Leu Arg Pro Gly Ser Leu Glu Arg Glu1               5                   10                  15Cys Lys Glu Glu Gln Cys Ser Phe Glu Glu Ala Arg Glu Ile Phe Lys            20                  25                  30Asp Ala Glu Arg Thr Lys Leu Phe Trp Ile Ser Tyr Ser Asp Gly Asp        35                  40                  45Gln Cys Ala Ser Ser Pro Cys Gln Asn Gly Gly Ser Cys Lys Asp Gln    50                  55                  60Leu Gln Ser Tyr Ile Cys Phe Cys Leu Pro Ala Phe Glu Gly Arg Asn65                  70                  75                  80Cys Glu Thr His Lys Asp Asp Gln Leu Ile Cys Val Asn Glu Asn Gly                85                  90                  95Gly Cys Glu Gln Tyr Cys Ser Asp His Thr Gly Thr Lys Arg Ser Cys            100                 105                 110Arg Cys His Glu Gly Tyr Ser Leu Leu Ala Asp Gly Val Ser Cys Thr        115                 120                 125Pro Thr Val Glu Tyr Pro Cys Gly Lys Ile Pro Ile Leu Glu Lys Arg    130                 135                 140Asn Ala Ser Lys Pro Gln Gly Arg Ile Val Gly Gly Lys Val Cys Pro145                 150                 155                 160Lys Gly Glu Cys Pro Trp Gln Val Leu Leu Leu Val Asn Gly Ala Gln                165                 170                 175Leu Cys Gly Gly Thr Leu Ile Asn Thr Ile Trp Val Val Ser Ala Ala            180                 185                 190His Cys Phe Asp Lys Ile Lys Asn Trp Arg Asn Leu Ile Ala Val Leu        195                 200                 205Gly Glu His Asp Leu Ser Glu His Asp Gly Asp Glu Gln Ser Arg Arg    210                 215                 220Val Ala Gln Val Ile Ile Pro Ser Thr Tyr Val Pro Gly Thr Thr Asn225                 230                 235                 240His Asp Ile Ala Leu Leu Arg Leu His Gln Pro Val Val Leu Thr Asp                245                 250                 255His Val Val Pro Leu Cys Leu Pro Glu Arg Thr Phe Ser Glu Arg Thr            260                 265                 270Leu Ala Phe Val Arg Phe Ser Leu Val Ser Gly Trp Gly Gln Leu Leu        275                 280                 285Asp Arg Gly Ala Thr Ala Leu Glu Leu Met Val Leu Asn Val Pro Arg    290                 295                 300Leu Met Thr Gln Asp Cys Leu Gln Gln Ser Arg Lys Val Gly Asp Ser305                 310                 315                 320Pro Asn Ile Thr Glu Tyr Met Phe Cys Ala Gly Tyr Ser Asp Gly Ser                325                 330                 335Lys Asp Ser Cys Lys Gly Asp Ser Gly Gly Pro His Ala Thr His Tyr            340                 345                 350Arg Gly Thr Trp Tyr Leu Thr Gly Ile Val Ser Trp Gly Gln Gly Cys        355                 360                 365Ala Thr Val Gly His Phe Gly Val Tyr Thr Arg Val Ser Gln Tyr Ile    370                 375                 380Glu Trp Leu Gln Lys Leu Met Arg Ser Glu Pro Arg Pro Gly Val Leu385                 390                 395                 400Leu Arg Ala Pro Phe Pro                405</s400><s200><s210>34</s210><s211>1218</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 34gccaacgcgt tcctggagga gctgcggccg ggctccctgg agagggagtg caaggaggag     60cagtgctcct tcgaggaggc ccgggagatc ttcaaggacg cggagaggac gaagctgttc    120tggatttctt acagtgatgg ggaccagtgt gcctcaagtc catgccagaa tgggggctcc    180tgcaaggacc agctccagtc ctatatctgc ttctgcctcc ctgccttcga gggccggaac    240tgtgagacgc acaaggatga ccagctgatc tgtgtgaacg agaacggcgg ctgtgagcag    300tactgcagtg accacacggg caccaagcgc tcctgtcggt gccacgaggg gtactctctg    360ctggcagacg gggtgtcctg cacacccaca gttgaatatc catgtggaaa aatacctatt    420ctagaaaaaa gaaatgccag caaaccccaa ggccgaattg tggggggcaa ggtgtgcccc    480aaaggggagt gtccatggca ggtcctgttg ttggtgaatg gagctcagtt gtgtgggggg    540accctgatca acaccatctg ggtggtctcc gcggcccact gtttcgacaa aatcaagaac    600tggaggaacc tgatcgcggt gctgggcgag cacgacctca gcgagcacga cggggatgag    660cagagccggc gggtggcgca ggtcatcatc cccagcacgt acgtcccggg caccaccaac    720cacgacatcg cgctgctccg cctgcaccag cccgtggtcc tcactgacca tgtggtgccc    780ctctgcctgc ccgaacggac gttctctgag aggacgctgg ccttcgtgcg cttctcattg    840gtcagcggct ggggccagct gctggaccgt ggcgccacgg ccctggagct catggtgctc    900aacgtgcccc ggctgatgac ccaggactgc ctgcagcagt cacggaaggt gggagactcc    960ccaaatatca cggagtacat gttctgtgcc ggctactcgg atggcagcaa ggactcctgc   1020aagggggaca gtggaggccc acatgccacc cactaccggg gcacgtggta cctgacgggc   1080atcgtcagct ggggccaggg ctgcgcaacc gtgggccact ttggggtgta caccagggtc   1140tcccagtaca tcgagtggct gcaaaagctc atgcgctcag agccacgccc aggagtcctc   1200ctgcgagccc catttccc                                                 1218</s400><s200><s210>35</s210><s211>33</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 35tatgcatggc gaaggcacct ttaccagcga tct                                  33</s400><s200><s210>36</s210><s211>62</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 36gagcaaacag atggaagaag aagcggtgcg cctgtttatt gaatggctga aaaacggcgg     60cc                                                                    62</s400><s200><s210>37</s210><s211>27</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 37cgagcagcgg cgcgccgccg ccgagcc                                         27</s400><s200><s210>38</s210><s211>35</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 38tcgaggctcg gcggcggcgc gccgctgctc gggcc                                35</s400><s200><s210>39</s210><s211>63</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 39gccgtttttc agccattcaa taaacaggcg caccgcttct tcttccatct gtttgctcag     60atc                                                                   63</s400><s200><s210>40</s210><s211>26</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 40gctggtaaag gtgccttcgc catgca                                          26</s400><s200><s210>41</s210><s211>51</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with      N-terminal Tev cleavage site</s223></s220></s200><s400> 41tatggaaaac ctgtatttcc aacatggcga aggcaccttt accagcgatc t              51</s400><s200><s210>42</s210><s211>44</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with      N-terminal Tev cleavage site</s223></s220></s200><s400> 42gctggtaaag gtgccttcgc catgttggaa atacaggttt tcca                      44</s400><s200><s210>43</s210><s211>66</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with      N-terminal Tev cleavage site and additional N-terminal sequence</s223></s220></s200><s400> 43tatggatatc ccaacgaccg aaaacctgta tttccaacat ggcgaaggca cctttaccag     60cgatct                                                                66</s400><s200><s210>44</s210><s211>59</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with      N-terminal Tev cleavage site and additional N-terminal sequence</s223></s220></s200><s400> 44gctggtaaag gtgccttcgc catgttggaa atacaggttt tcggtcgttg ggatatcca      59</s400><s200><s210>45</s210><s211>87</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with DsbA      leader sequence</s223></s220></s200><s400> 45tatgaaaaag atttggctgg cgctggctgg tttagtttta gcgtttagcg catcggcgca     60tggcgaaggc acctttacca gcgatct                                         87</s400><s200><s210>46</s210><s211>80</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Exendin-4/ELP sequence with DsbA      leader sequence</s223></s220></s200><s400> 46gctggtaaag gtgccttcgc catgcgccga tgcgctaaac gctaaaacta aaccagccag     60cgccagccaa atctttttca                                                 80</s400><s200><s210>47</s210><s211>39</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Insulin/ELP sequence</s223></s220></s200><s400> 47gaaggagata tacatatgtt tgtgaaccaa cacctgtgc                            39</s400><s200><s210>48</s210><s211>30</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>Primer for Insulin/ELP sequence</s223></s220></s200><s400> 48cccatgccct cgaggttgca gtagttctcc                                      30</s400><s200><s210>49</s210><s211>27</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 49ctagctagca tggtctccca ggccctc                                         27</s400><s200><s210>50</s210><s211>33</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 50tattcttgcg gccgcgggaa atggggctcg cag                                  33</s400><s200><s210>51</s210><s211>261</s211><s212>DNA</s212><s213>Homo sapiens</s213></s200><s400> 51atgtttgtga accaacacct gtgcggctca cacctggtgg aagctctcta cctagtgtgc     60ggggaacgag gcttcttcta cacacccaag acccgccggg aggcagagga cctgcaggtg    120gggcaggtgg agctgggcgg gggccctggt gcaggcagcc tgcagccctt ggccctggag    180gggtccctgc agaagcgtgg cattgtggaa caatgctgta ccagcatctg ctccctctac    240cagctggaga actactgcaa c                                              261</s400><s200><s210>52</s210><s211>87</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 52Met Phe Val Asn Gln His Leu Cys Gly Ser His Leu Val Glu Ala Leu1               5                   10                  15Tyr Leu Val Cys Gly Glu Arg Gly Phe Phe Tyr Thr Pro Lys Thr Arg            20                  25                  30Arg Glu Ala Glu Asp Leu Gln Val Gly Gln Val Glu Leu Gly Gly Gly        35                  40                  45Pro Gly Ala Gly Ser Leu Gln Pro Leu Ala Leu Glu Gly Ser Leu Gln    50                  55                  60Lys Arg Gly Ile Val Glu Gln Cys Cys Thr Ser Ile Cys Ser Leu Tyr65                  70                  75                  80Gln Leu Glu Asn Tyr Cys Asn                85</s400><s200><s210>53</s210><s211>1700</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>pPB0868 DNA sequence</s223></s220></s200><s400> 53taatacgact cactataggg gaattgtgag cggataacaa ttcccctcta gaaataattt     60tgtttaactt taagaaggag atatacatat ggagaacctg tatttccaac atggcgaagg    120tacctttaca agcgatgtta gttcatatct ggagggccag gcggcaaagg aattcattgc    180gtggctggtg aaaggccgcg gcctcgaggg catgggtggg ccgggcgtgg gtgttccggg    240cgtgggtgtt ccgggtggcg gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg    300tgttggtgtg ccgggtgttg gtgtaccagg tggcggtgtt ccgggtgcag gcgttccggg    360tggcggtgtg ccgggcgtgg gtgttccggg cgtgggtgtt ccgggtggcg gtgtgccggg    420cgcaggtgtt cctggtgtag gtgtgccggg tgttggtgtg ccgggtgttg gtgtaccagg    480tggcggtgtt ccgggtgcag gcgttccggg tggcggtgtg ccgggcgtgg gtgttccggg    540cgtgggtgtt ccgggtggcg gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg    600tgttggtgtg ccgggtgttg gtgtaccagg tggcggtgtt ccgggtgcag gcgttccggg    660tggcggtgtg ccgggcgtgg gtgttccggg cgtgggtgtt ccgggtggcg gtgtgccggg    720cgcaggtgtt cctggtgtag gtgtgccggg tgttggtgtg ccgggtgttg gtgtaccagg    780tggcggtgtt ccgggtgcag gcgttccggg tggcggtgtg ccgggcgtgg gtgttccggg    840cgtgggtgtt ccgggtggcg gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg    900tgttggtgtg ccgggtgttg gtgtaccagg tggcggtgtt ccgggtgcag gcgttccggg    960tggcggtgtg ccgggcgtgg gtgttccggg cgtgggtgtt ccgggtggcg gtgtgccggg   1020cgcaggtgtt cctggtgtag gtgtgccggg tgttggtgtg ccgggtgttg gtgtaccagg   1080tggcggtgtt ccgggtgcag gcgttccggg tggcggtgtg ccgggcgtgg gtgttccggg   1140cgtgggtgtt ccgggtggcg gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg   1200tgttggtgtg ccgggtgttg gtgtaccagg tggcggtgtt ccgggtgcag gcgttccggg   1260tggcggtgtg ccgggcgtgg gtgttccggg cgtgggtgtt ccgggtggcg gtgtgccggg   1320cgcaggtgtt cctggtgtag gtgtgccggg tgttggtgtg ccgggtgttg gtgtaccagg   1380tggcggtgtt ccgggtgcag gcgttccggg tggcggtgtg ccgggcgtgg gtgttccggg   1440cgtgggtgtt ccgggtggcg gtgtgccggg cgcaggtgtt cctggtgtag gtgtgccggg   1500tgttggtgtg ccgggtgttg gtgtaccagg tggcggtgtt ccgggtgcag gcgttccggg   1560tggcggtgtg ccgggctggc cgtgataagc tagcatgact ggtggacagc aaatgggtcg   1620gatccgaatt cgagctccgt cgagcaccac caccaccacc actgagatcc ggctgctaac   1680aaagcccgaa aggaagctga                                               1700</s400><s200><s210>54</s210><s211>498</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1(A8G,7-37)ELP1-90 amino acid sequence</s223></s220></s200><s400> 54Met Glu Asn Leu Tyr Phe Gln His Gly Glu Gly Thr Phe Thr Ser Asp1               5                   10                  15Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp            20                  25                  30Leu Val Lys Gly Arg Gly Leu Glu Gly Met Gly Gly Pro Gly Val Gly        35                  40                  45Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val    50                  55                  60Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro65                  70                  75                  80Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly                85                  90                  95Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala            100                 105                 110Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly        115                 120                 125Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val    130                 135                 140Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro145                 150                 155                 160Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly                165                 170                 175Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly            180                 185                 190Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly        195                 200                 205Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val    210                 215                 220Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro225                 230                 235                 240Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly                245                 250                 255Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val            260                 265                 270Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly        275                 280                 285Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val    290                 295                 300Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro305                 310                 315                 320Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly                325                 330                 335Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val            340                 345                 350Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly        355                 360                 365Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val    370                 375                 380Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro385                 390                 395                 400Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly                405                 410                 415Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly            420                 425                 430Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly        435                 440                 445Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val    450                 455                 460Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro465                 470                 475                 480Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly                485                 490                 495Trp Pro</s400><s200><s210>55</s210><s211>2050</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>pPB1022 DNA sequence</s223></s220></s200><s400> 55taatacgact cactataggg gaattgtgag cggataacaa ttcccctcta gaaataattt     60tgtttaactt taagaaggag atatacatat ggagaacctg tatttccaac atggcgaagg    120tacctttaca agcgatgtta gttcatatct ggagggccag gcggcaaagg aatttattgc    180gtggctggtg aaaggccgcg gcgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg    240tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg    300tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg    360cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg    420tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg    480tgcaggcgtt ccgggtggcg gtgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg    540tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg    600tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg    660cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg    720tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg    780tgcaggcgtt ccgggtggcg gtgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg    840tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg    900tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg    960cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg   1020tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg   1080tgcaggcgtt ccgggtggcg gtgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg   1140tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg   1200tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg   1260cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg   1320tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg   1380tgcaggcgtt ccgggtggcg gtgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg   1440tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg   1500tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg   1560cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg   1620tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg   1680tgcaggcgtt ccgggtggcg gtgtgccggg cgtgggtgtt ccgggcgtgg gtgttccggg   1740tggcggtgtg ccgggcgcag gtgttcctgg tgtaggtgtg ccgggtgttg gtgtgccggg   1800tgttggtgta ccaggtggcg gtgttccggg tgcaggcgtt ccgggtggcg gtgtgccggg   1860cgtgggtgtt ccgggcgtgg gtgttccggg tggcggtgtg ccgggcgcag gtgttcctgg   1920tgtaggtgtg ccgggtgttg gtgtgccggg tgttggtgta ccaggtggcg gtgttccggg   1980tgcaggcgtt ccgggtggcg gtgtgccggg ctggccgtga taagctagca tgactggtgg   2040acagcaaatg                                                          2050</s400><s200><s210>56</s210><s211>643</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>GLP-1(A8G,7-37)ELP1-120 amino acid sequence</s223></s220></s200><s400> 56Met Glu Asn Leu Tyr Phe Gln His Gly Glu Gly Thr Phe Thr Ser Asp1               5                   10                  15Val Ser Ser Tyr Leu Glu Gly Gln Ala Ala Lys Glu Phe Ile Ala Trp            20                  25                  30Leu Val Lys Gly Arg Gly Val Pro Gly Val Gly Val Pro Gly Val Gly        35                  40                  45Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val    50                  55                  60Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro65                  70                  75                  80Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly                85                  90                  95Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val            100                 105                 110Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly        115                 120                 125Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val    130                 135                 140Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro145                 150                 155                 160Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly                165                 170                 175Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val            180                 185                 190Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly        195                 200                 205Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val    210                 215                 220Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro225                 230                 235                 240Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly                245                 250                 255Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val            260                 265                 270Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly        275                 280                 285Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val    290                 295                 300Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro305                 310                 315                 320Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly                325                 330                 335Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly            340                 345                 350Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly        355                 360                 365Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val    370                 375                 380Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro385                 390                 395                 400Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly                405                 410                 415Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala            420                 425                 430Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly        435                 440                 445Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val    450                 455                 460Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro465                 470                 475                 480Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly                485                 490                 495Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val            500                 505                 510Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly        515                 520                 525Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val    530                 535                 540Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro545                 550                 555                 560Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly                565                 570                 575Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val            580                 585                 590Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly        595                 600                 605Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val    610                 615                 620Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro625                 630                 635                 640Gly Trp Pro</s400><s200><s210>57</s210><s211>3700</s211><s212>DNA</s212><s213>Artificial Sequence</s213><s220><s223>pPB0788 DNA sequence</s223></s220></s200><s400> 57gacggatcgg gagatctccc gatcccctat ggtgcactct cagtacaatc tgctctgatg     60ccgcatagtt aagccagtat ctgctccctg cttgtgtgtt ggaggtcgct gagtagtgcg    120cgagcaaaat ttaagctaca acaaggcaag gcttgaccga caattgcatg aagaatctgc    180ttagggttag gcgttttgcg ctgcttcgcg atgtacgggc cagatatacg cgttgacatt    240gattattgac tagttattaa tagtaatcaa ttacggggtc attagttcat agcccatata    300tggagttccg cgttacataa cttacggtaa atggcccgcc tggctgaccg cccaacgacc    360cccgcccatt gacgtcaata atgacgtatg ttcccatagt aacgccaata gggactttcc    420attgacgtca atgggtggag tatttacggt aaactgccca cttggcagta catcaagtgt    480atcatatgcc aagtacgccc cctattgacg tcaatgacgg taaatggccc gcctggcatt    540atgcccagta catgacctta tgggactttc ctacttggca gtacatctac gtattagtca    600tcgctattac catggtgatg cggttttggc agtacatcaa tgggcgtgga tagcggtttg    660actcacgggg atttccaagt ctccacccca ttgacgtcaa tgggagtttg ttttggcacc    720aaaatcaacg ggactttcca aaatgtcgta acaactccgc cccattgacg caaatgggcg    780gtaggcgtgt acggtgggag gtctatataa gcagagctct ctggctaact agagaaccca    840ctgcttactg gcttatcgaa attaatacga ctcactatag ggagacccaa gctggctagc    900atggtctccc aggccctcag gctcctctgc cttctgcttg ggcttcaggg ctgcctggct    960gcagtcttcg taacccagga ggaagcccac ggcgtcctgc accggcgccg gcgcgccaac   1020gcgttcctgg aggagctacg gccgggctcc ctggagaggg agtgcaagga ggagcagtgc   1080tccttcgagg aggcccggga gatcttcaag gacgcggaga ggacgaagct gttctggatt   1140tcttacagtg atggggacca gtgtgcctca agtccatgcc agaatggggg ctcctgcaag   1200gaccagctcc agtcctatat ctgcttctgc ctccctgcct tcgagggccg gaactgtgag   1260acgcacaagg atgaccagct gatctgtgtg aacgagaacg gcggctgtga gcagtactgc   1320agtgaccaca cgggcaccaa gcgctcctgt cggtgccacg aggggtactc tctgctggca   1380gacggggtgt cctgcacacc cacagttgaa tatccatgtg gaaaaatacc tattctagaa   1440aaaagaaatg ccagcaaacc ccaaggccga attgtggggg gcaaggtgtg ccccaaaggg   1500gagtgtccat ggcaggtcct gttgttggtg aatggagctc agttgtgtgg ggggaccctg   1560atcaacacca tctgggtggt ctccgcggcc cactgtttcg acaaaatcaa gaactggagg   1620aacctgatcg cggtgctggg cgagcacgac ctcagcgagc acgacgggga tgagcagagc   1680cggcgggtgg cgcaggtcat catccccagc acgtacgtcc cgggcaccac caaccacgac   1740atcgcgctgc tccgcctgca ccagcccgtg gtcctcactg accatgtggt gcccctctgc   1800ctgcccgaac ggacgttctc tgagaggacg ctggccttcg tgcgcttctc attggtcagc   1860ggctggggcc agctgctgga ccgtggcgcc acggccctgg agctcatggt cctcaacgtg   1920ccccggctga tgacccagga ctgcctgcag cagtcacgga aggtgggaga ctccccaaat   1980atcacggagt acatgttctg tgccggctac tcggatggca gcaaggactc ctgcaagggg   2040gacagtggag gcccacatgc cacccactac cggggcacgt ggtacctgac gggcatcgtc   2100agctggggcc agggctgcgc aaccgtgggc cactttgggg tgtacaccag ggtctcccag   2160tacatcgagt ggctgcaaaa gctcatgcgc tcagagccac gcccaggagt cctcctgcga   2220gccccatttc ccgcggccgc tgaaaacctg tattttcagg gtggggccgc tgggccgggc   2280gtgggagttc ccggcgtggg agttcccgga ggcggagtgc ccggcgcagg agttcctgga   2340gtcggagtgc ccggagttgg agtgcccgga gttggagtcc caggaggcgg agtccccgga   2400gcaggcgtcc ccggaggcgg agtgccgggc gtgggagttc ccggcgtggg agttcccgga   2460ggcggagtgc ccggcgcagg agttcctgga gtcggagtgc ccggagttgg agtgcccgga   2520gttggagtcc caggaggcgg agtccccgga gcaggcgtcc ccggaggcgg agtgccgggc   2580gtgggagttc ccggcgtggg agttcccgga ggcggagtgc ccggcgcagg agttcctgga   2640gtcggagtgc ccggagttgg agtgcccgga gttggagtcc caggaggcgg agtccccgga   2700gcaggcgtcc ccggaggcgg agtgccgggc gtgggagttc ccggcgtggg agttcccgga   2760ggcggagtgc ccggcgcagg agttcctgga gtcggagtgc ccggagttgg agtgcccgga   2820gttggagtcc caggaggcgg agtccccgga gcaggcgtcc ccggaggcgg agtgccgggc   2880gtgggagttc ccggcgtggg agttcccgga ggcggagtgc ccggcgcagg agttcctgga   2940gtcggagtgc ccggagttgg agtgcccgga gttggagtcc caggaggcgg agtccccgga   3000gcaggcgtcc ccggaggcgg agtgccgggc gtgggagttc ccggcgtggg agttcccgga   3060ggcggagtgc ccggcgcagg agttcctgga gtcggagtgc ccggagttgg agtgcccgga   3120gttggagtcc caggaggcgg agtccccgga gcaggcgtcc ccggaggcgg agtgccgggc   3180gtgggagttc ccggcgtggg agttcccgga ggcggagtgc ccggcgcagg agttcctgga   3240gtcggagtgc ccggagttgg agtgcccgga gttggagtcc caggaggcgg agtccccgga   3300gcaggcgtcc ccggaggcgg agtgccgggc gtgggagttc ccggcgtggg agttcccgga   3360ggcggagtgc ccggcgcagg agttcctgga gtcggagtgc ccggagttgg agtgcccgga   3420gttggagtcc caggaggcgg agtccccgga gcaggcgtcc ccggaggcgg agtgccgggc   3480gtgggagttc ccggcgtggg agttcccgga ggcggagtgc ccggcgcagg agttcctgga   3540gtcggagtgc ccggagttgg agtgcccgga gttggagtcc caggaggcgg agtccccgga   3600gcaggcgtcc ccggaggcgg agtgccgggc tggccttgat gactcgagtc tagagggccc   3660gtttaaaccc gctgatcagc ctcgactgtg ccttctagtt                         3700</s400><s200><s210>58</s210><s211>912</s211><s212>PRT</s212><s213>Artificial Sequence</s213><s220><s223>Factor VIP-ELP 1-90 amino acid sequence</s223></s220></s200><s400> 58Met Val Ser Gln Ala Leu Arg Leu Leu Cys Leu Leu Leu Gly Leu Gln1               5                   10                  15Gly Cys Leu Ala Ala Val Phe Val Thr Gln Glu Glu Ala His Gly Val            20                  25                  30Leu His Arg Arg Arg Arg Ala Asn Ala Phe Leu Glu Glu Leu Arg Pro        35                  40                  45Gly Ser Leu Glu Arg Glu Cys Lys Glu Glu Gln Cys Ser Phe Glu Glu    50                  55                  60Ala Arg Glu Ile Phe Lys Asp Ala Glu Arg Thr Lys Leu Phe Trp Ile65                  70                  75                  80Ser Tyr Ser Asp Gly Asp Gln Cys Ala Ser Ser Pro Cys Gln Asn Gly                85                  90                  95Gly Ser Cys Lys Asp Gln Leu Gln Ser Tyr Ile Cys Phe Cys Leu Pro            100                 105                 110Ala Phe Glu Gly Arg Asn Cys Glu Thr His Lys Asp Asp Gln Leu Ile        115                 120                 125Cys Val Asn Glu Asn Gly Gly Cys Glu Gln Tyr Cys Ser Asp His Thr    130                 135                 140Gly Thr Lys Arg Ser Cys Arg Cys His Glu Gly Tyr Ser Leu Leu Ala145                 150                 155                 160Asp Gly Val Ser Cys Thr Pro Thr Val Glu Tyr Pro Cys Gly Lys Ile                165                 170                 175Pro Ile Leu Glu Lys Arg Asn Ala Ser Lys Pro Gln Gly Arg Ile Val            180                 185                 190Gly Gly Lys Val Cys Pro Lys Gly Glu Cys Pro Trp Gln Val Leu Leu        195                 200                 205Leu Val Asn Gly Ala Gln Leu Cys Gly Gly Thr Leu Ile Asn Thr Ile    210                 215                 220Trp Val Val Ser Ala Ala His Cys Phe Asp Lys Ile Lys Asn Trp Arg225                 230                 235                 240Asn Leu Ile Ala Val Leu Gly Glu His Asp Leu Ser Glu His Asp Gly                245                 250                 255Asp Glu Gln Ser Arg Arg Val Ala Gln Val Ile Ile Pro Ser Thr Tyr            260                 265                 270Val Pro Gly Thr Thr Asn His Asp Ile Ala Leu Leu Arg Leu His Gln        275                 280                 285Pro Val Val Leu Thr Asp His Val Val Pro Leu Cys Leu Pro Glu Arg    290                 295                 300Thr Phe Ser Glu Arg Thr Leu Ala Phe Val Arg Phe Ser Leu Val Ser305                 310                 315                 320Gly Trp Gly Gln Leu Leu Asp Arg Gly Ala Thr Ala Leu Glu Leu Met                325                 330                 335Val Leu Asn Val Pro Arg Leu Met Thr Gln Asp Cys Leu Gln Gln Ser            340                 345                 350Arg Lys Val Gly Asp Ser Pro Asn Ile Thr Glu Tyr Met Phe Cys Ala        355                 360                 365Gly Tyr Ser Asp Gly Ser Lys Asp Ser Cys Lys Gly Asp Ser Gly Gly    370                 375                 380Pro His Ala Thr His Tyr Arg Gly Thr Trp Tyr Leu Thr Gly Ile Val385                 390                 395                 400Ser Trp Gly Gln Gly Cys Ala Thr Val Gly His Phe Gly Val Tyr Thr                405                 410                 415Arg Val Ser Gln Tyr Ile Glu Trp Leu Gln Lys Leu Met Arg Ser Glu            420                 425                 430Pro Arg Pro Gly Val Leu Leu Arg Ala Pro Phe Pro Ala Ala Ala Glu        435                 440                 445Asn Leu Tyr Phe Gln Gly Gly Ala Ala Gly Pro Gly Val Gly Val Pro    450                 455                 460Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly465                 470                 475                 480Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly                485                 490                 495Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly            500                 505                 510Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val        515                 520                 525Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro    530                 535                 540Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly545                 550                 555                 560Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala                565                 570                 575Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly            580                 585                 590Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val        595                 600                 605Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro    610                 615                 620Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly625                 630                 635                 640Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Gly                645                 650                 655Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly            660                 665                 670Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val        675                 680                 685Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro    690                 695                 700Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly705                 710                 715                 720Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro Gly Val                725                 730                 735Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly            740                 745                 750Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val        755                 760                 765Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly Val Pro    770                 775                 780Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly785                 790                 795                 800Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro Gly Val                805                 810                 815Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly Val Gly            820                 825                 830Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly Gly Val        835                 840                 845Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Val Gly Val Pro    850                 855                 860Gly Val Gly Val Pro Gly Gly Gly Val Pro Gly Ala Gly Val Pro Gly865                 870                 875                 880Val Gly Val Pro Gly Val Gly Val Pro Gly Val Gly Val Pro Gly Gly                885                 890                 895Gly Val Pro Gly Ala Gly Val Pro Gly Gly Gly Val Pro Gly Trp Pro            900                 905                 910</s400><s200><s210>59</s210><s211>31</s211><s212>PRT</s212><s213>Unknown</s213><s220><s223>GLP-1 receptor agonist</s223></s220></s200><s400> 59His Gly Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly1               5                   10                  15Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg Gly            20                  25                  30</s400><s200><s210>60</s210><s211>31</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 60His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro            20                  25                  30</s400><s200><s210>61</s210><s211>30</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 61His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly            20                  25                  30</s400><s200><s210>62</s210><s211>32</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 62His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30</s400><s200><s210>63</s210><s211>33</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 63His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser</s400><s200><s210>64</s210><s211>34</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 64His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly</s400><s200><s210>65</s210><s211>35</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 65His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala        35</s400><s200><s210>66</s210><s211>36</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 66His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala Pro</s400><s200><s210>67</s210><s211>37</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 67His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala Pro Pro        35</s400><s200><s210>68</s210><s211>38</s211><s212>PRT</s212><s213>Homo sapiens</s213></s200><s400> 68His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu1               5                   10                  15Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser            20                  25                  30Ser Gly Ala Pro Pro Pro        35</s400></sequence-list-new-rules></sequence-cwu><?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v46-2022-02-17.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.6 2022-02-17" file="US20230000953A1-20230105.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20221221" date-publ="20230105"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20230000953</doc-number><kind>A1</kind><date>20230105</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>17903074</doc-number><date>20220906</date></document-id></application-reference><us-application-series-code>17</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>16</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>19</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>00</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>A</section><class>61</class><subclass>P</subclass><main-group>3</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>38</main-group><subgroup>28</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc><further-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>1652</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>1611</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>19</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>1694</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>K</subclass><main-group>9</main-group><subgroup>0095</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc><classification-cpc><cpc-version-indicator><date>20180101</date></cpc-version-indicator><section>A</section><class>61</class><subclass>P</subclass><main-group>3</main-group><subgroup>02</subgroup><symbol-position>L</symbol-position><classification-value>I</classification-value><action-date><date>20230105</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></further-cpc></classifications-cpc><invention-title id="d2e43">INSULIN FORMULATIONS AND METHODS OF USING SAME IN PRETERM INFANTS</invention-title><us-related-documents><continuation><relation><parent-doc><document-id><country>US</country><doc-number>PCT/IL2022/050371</doc-number><date>20220411</date></document-id><parent-status>PENDING</parent-status></parent-doc><child-doc><document-id><country>US</country><doc-number>17903074</doc-number></document-id></child-doc></relation></continuation><us-provisional-application><document-id><country>US</country><doc-number>63173442</doc-number><date>20210411</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="obligated-assignee"><addressbook><orgname>Elgan Pharma Ltd</orgname><address><city>Nazareth</city><country>IL</country></address></addressbook><residence><country>IL</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>OLSHANSKY</last-name><first-name>Michal</first-name><address><city>Tel Aviv</city><country>IL</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>OSTROVSKY</last-name><first-name>Elena</first-name><address><city>Rishon-LeZion</city><country>IL</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>ZELDIS</last-name><first-name>Stav</first-name><address><city>Herzeliya</city><country>IL</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Elgan Pharma Ltd</orgname><role>03</role><address><city>Nazareth</city><country>IL</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">An insulin formulation and a method of preparing and using same. The insulin preparation includes insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively) with ranges of A and B are 1000-5000 and 10-50, respectively.</p></abstract><drawings id="DRAWINGS"><figure id="Fig-EMI-D00000" num="00000"><img id="EMI-D00000" he="142.41mm" wi="158.75mm" file="US20230000953A1-20230105-D00000.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00001" num="00001"><img id="EMI-D00001" he="229.79mm" wi="166.37mm" file="US20230000953A1-20230105-D00001.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00002" num="00002"><img id="EMI-D00002" he="109.30mm" wi="165.95mm" file="US20230000953A1-20230105-D00002.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00003" num="00003"><img id="EMI-D00003" he="213.61mm" wi="155.11mm" orientation="landscape" file="US20230000953A1-20230105-D00003.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00004" num="00004"><img id="EMI-D00004" he="198.97mm" wi="160.02mm" orientation="landscape" file="US20230000953A1-20230105-D00004.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00005" num="00005"><img id="EMI-D00005" he="204.64mm" wi="160.27mm" orientation="landscape" file="US20230000953A1-20230105-D00005.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00006" num="00006"><img id="EMI-D00006" he="213.11mm" wi="164.51mm" orientation="landscape" file="US20230000953A1-20230105-D00006.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00007" num="00007"><img id="EMI-D00007" he="172.80mm" wi="144.95mm" file="US20230000953A1-20230105-D00007.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00008" num="00008"><img id="EMI-D00008" he="242.82mm" wi="164.51mm" file="US20230000953A1-20230105-D00008.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure><figure id="Fig-EMI-D00009" num="00009"><img id="EMI-D00009" he="235.71mm" wi="165.69mm" orientation="landscape" file="US20230000953A1-20230105-D00009.TIF" alt="embedded image" img-content="drawing" img-format="tif"/></figure></drawings><description id="description"><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="lead"?><heading id="h-0001" level="1">RELATED APPLICATIONS</heading><p id="p-0002" num="0001">This application is a Continuation of PCT Patent Application No. PCT/IL2022/050371 having International filing date of Apr. 11, 2022, which claims the benefit of priority under 35 USC &#xa7; 119(e) of U.S. Provisional Patent Application No. 63/173,442 filed on Apr. 11, 2021. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.</p><?cross-reference-to-related-applications description="Cross Reference To Related Applications" end="tail"?><?summary-of-invention description="Summary of Invention" end="lead"?><heading id="h-0002" level="1">FIELD AND BACKGROUND OF THE INVENTION</heading><p id="p-0003" num="0002">The present invention relates to insulin formulation formulated for use in infant feed. Embodiments of the present invention relate to methods of preparing insulin and an infant feed including same and to methods of using the insulin-containing infant feed in preventing or reducing severity of pre-term infant disorders such as late onset sepsis or necrotizing enterocolitis/colitis/enterocolitis.</p><p id="p-0004" num="0003">Birth is considered premature, or preterm, when it occurs before the 37th week of pregnancy. The final weeks in the womb are crucial for healthy weight gain and for the full development of various vital organs.</p><p id="p-0005" num="0004">Human milk is recognized as the optimal feeding for all infants including pre-term infants because of its proven health benefits to infants.</p><p id="p-0006" num="0005">Human milk contains a substantial number of hormones and growth factors and studies have shown that some of these hormones (e.g. insulin, insulin-like growth factor 1, IGF-1, epidermal growth factors) have an effect on the small intestine following oral administration.</p><p id="p-0007" num="0006">Studies have also shown that that addition of insulin to preterm infant formulas results in better growth and accelerated intestinal maturation [Shulman, R. J., 2002; Archives of Disease in Childhood-Fetal and Neonatal Edition, 86(2), F131-F133].</p><p id="p-0008" num="0007">While insulin-containing infant feed formulations have been previously described</p><p id="p-0009" num="0008">When infants are born prematurely, their digestive systems may not be fully developed and as a result, many of these pre-term infants experience feeding difficulties and disorders that directly or indirectly relate to malnourishment.</p><p id="p-0010" num="0009">Late-onset sepsis (LOS), defined as sepsis onset after 72 h of life, is a leading cause of mortality in the neonatal intensive care unit. The incidence rates for LOS in preterm infants vary between 20 and 38% in the first 120 days of life, and mortality rates range from 13 to 19%.</p><p id="p-0011" num="0010">Necrotizing enterocolitis (NEC) is a disease that affects mostly the intestine of premature infants. The wall of the intestine is invaded by bacteria, which cause local infection and inflammation that can ultimately destroy the wall of the intestine. About 7% of pre-term infants develop necrotizing enterocolitis and among those affected, about 25% die.</p><p id="p-0012" num="0011">While reducing the present invention to practice, the present inventors have formulated an insulin formulation that can be solubilized in an infant feed (formula or breast milk) and have shown for the first time that such a feed formulation can be used to prevent, or reduce the severity of LOS and NEC.</p><heading id="h-0003" level="1">SUMMARY OF THE INVENTION</heading><p id="p-0013" num="0012">According to one aspect of the present invention there is provided a method of preparing insulin for use in an infant feed comprising: solubilizing insulin in hydrochloric acid to obtain solubilized insulin; and diluting the solubilized insulin with water and adjusting a pH to 6.9-8.0.</p><p id="p-0014" num="0013">According to embodiments of the present invention the method further comprises adding cyclodextrin to solution (b) to thereby encapsulate the insulin in cyclodextrin cavities; and adjusting pH to 6.9-8.0.</p><p id="p-0015" num="0014">According to embodiments of the present invention the method further comprises compounding a result of (b) or (d) with a sodium chloride solution and a maltodextrin solution and adjusting the pH to 6.7-7.6.</p><p id="p-0016" num="0015">According to embodiments of the present invention the composition is combined with an oil-in-water nanodroplets emulsion wherein the nanodroplets include the Docosahexaenoic acid (DHA) and the coenzyme Q10.</p><p id="p-0017" num="0016">According to embodiments of the present invention the method further comprises filtering a result of the compounding and lyophilizing a filtrate to obtain an amorphous powder with a pH 6.0-7.6</p><p id="p-0018" num="0017">According to another aspect of the present invention there is provided a method of producing an infant feed with insulin comprising reconstituting the amorphous powder described herein in the infant feed.</p><p id="p-0019" num="0018">According to another aspect of the present invention there is provided an insulin formulation comprising insulin, oligosaccharide and sodium chloride at a ratio of 1:A:B (w:w:w respectively), wherein ranges of A and B are 1000-100,000 and 10-50, respectively.</p><p id="p-0020" num="0019">According to embodiments of the present invention the insulin formulation has a pH of 6.0-7.6 when reconstituted in deionized water or 0.9% sodium chloride solution at concentration of 0.03 g/ml.</p><p id="p-0021" num="0020">According to embodiments of the present invention the insulin formulation further comprises cyclodextrin.</p><p id="p-0022" num="0021">According to embodiments of the present invention the cyclodextrin is at a ratio of 10-1000 with respect to the insulin.</p><p id="p-0023" num="0022">According to embodiments of the present invention 1 gram of the insulin formulation includes 2-40 IU.</p><p id="p-0024" num="0023">According to another aspect of the present invention there is provided an infant feed comprising the insulin formulation.</p><p id="p-0025" num="0024">According to another aspect of the present invention there is provided a method of preventing necrotizing enterocolitis/colitis/enterocolitis in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0026" num="0025">According to another aspect of the present invention there is provided a method of reducing the prevalence and severity of necrotizing enterocolitis/colitis/enterocolitis in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0027" num="0026">According to another aspect of the present invention there is provided a method of reducing the prevalence of late-onset sepsis in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0028" num="0027">According to another aspect of the present invention there is provided a method of reducing inflammation in the gastrointestinal in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0029" num="0028">According to another aspect of the present invention there is provided a method of reducing the prevalence and severity of adverse events, life-threatening events and fatal complications in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0030" num="0029">According to another aspect of the present invention there is provided a method of reducing permeability of the GI tract in a preterm infant comprising administering to the preterm infant the infant feed and measuring a lactose/lactulose ratio.</p><p id="p-0031" num="0030">According to another aspect of the present invention there is provided a method of increasing the rapid maturation of the gut microbiota in a preterm infant comprising administering to the preterm infant the infant feed and measuring a reduction in Proteobacteria and an increase in Firmicutes and Clostridiaceae.</p><p id="p-0032" num="0031">According to embodiments of the present invention the infant feed includes 0.01-4 IU/ml.</p><p id="p-0033" num="0032">According to another aspect of the present invention there is provided a method of preventing late onset sepsis in a preterm infant comprising administering to the preterm infant the infant feed.</p><p id="p-0034" num="0033">According to another aspect of the present invention there is provided a method of reducing a discharge time from primary care of a preterm infant comprising administering to the preterm infant the infant feed disclosed herein.</p><p id="p-0035" num="0034">Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In case of conflict, the patent specification, including definitions, will control. In addition, the materials, methods, and examples are illustrative only and not intended to be limiting.</p><?summary-of-invention description="Summary of Invention" end="tail"?><?brief-description-of-drawings description="Brief Description of Drawings" end="lead"?><description-of-drawings><heading id="h-0004" level="1">BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWINGS</heading><p id="p-0036" num="0035">The invention is herein described, by way of example only, with reference to the accompanying drawings. With specific reference now to the drawings in detail, it is stressed that the particulars shown are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only, and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for a fundamental understanding of the invention, the description taken with the drawings making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.</p><p id="p-0037" num="0036">In the drawings:</p><p id="p-0038" num="0037"><figref idref="DRAWINGS">FIG. <b>1</b></figref> is a typical chromatogram of formulations I-IV of the present invention.</p><p id="p-0039" num="0038"><figref idref="DRAWINGS">FIG. <b>2</b></figref> is a typical chromatogram of formulations V-VI of the present invention.</p><p id="p-0040" num="0039"><figref idref="DRAWINGS">FIG. <b>3</b></figref> is a typical chromatogram of DHA and Coenzyme Q10 in formulations IV-V of the present invention.</p><p id="p-0041" num="0040"><figref idref="DRAWINGS">FIG. <b>4</b></figref> illustrates the Probability of parenteral nutrition (PN) wean-off per group (Kaplan-Meier survival curve).</p><p id="p-0042" num="0041"><figref idref="DRAWINGS">FIG. <b>5</b></figref> illustrates the average PN intake per day per group, presenting a clear benefit of the treatment group, especially for the Enteral insulin formulation at 0.3 IU/kg/day compared to placebo (shown as the rate of PN reduction out of total intake).</p><p id="p-0043" num="0042"><figref idref="DRAWINGS">FIG. <b>6</b></figref> illustrates the percentage of enteral nutrition out of total nutrition per group.</p><p id="p-0044" num="0043"><figref idref="DRAWINGS">FIG. <b>7</b></figref> illustrates the resents the trajectories per group of <figref idref="DRAWINGS">FIG. <b>6</b></figref>.</p><p id="p-0045" num="0044"><figref idref="DRAWINGS">FIG. <b>8</b></figref> is a scanning electron micrograph showing the amorphous structure of formulations I-IV of the present invention.</p><p id="p-0046" num="0045"><figref idref="DRAWINGS">FIGS. <b>9</b>-<b>10</b></figref> are graphs showing thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC) of formulations I-IV of the present invention.</p><p id="p-0047" num="0046"><figref idref="DRAWINGS">FIG. <b>11</b></figref> is a solid-state NMR spectrum of formulation I-IV of the present invention.</p></description-of-drawings><?brief-description-of-drawings description="Brief Description of Drawings" end="tail"?><?detailed-description description="Detailed Description" end="lead"?><heading id="h-0005" level="1">DESCRIPTION OF SPECIFIC EMBODIMENTS OF THE INVENTION</heading><p id="p-0048" num="0047">The present invention is of an insulin formulation which can be used in an infant feed. Specifically, the present invention can be used to prevent or reduce severity of pre-term infant disorders such as late onset sepsis or necrotizing enterocolitis/colitis/enterocolitis.</p><p id="p-0049" num="0048">The principles and operation of the present invention may be better understood with reference to the drawings and accompanying descriptions.</p><p id="p-0050" num="0049">Before explaining at least one embodiment of the invention in detail, it is to be understood that the invention is not limited in its application to the details set forth in the following description or exemplified by the Examples. The invention is capable of other embodiments or of being practiced or carried out in various ways. Also, it is to be understood that the phraseology and terminology employed herein is for the purpose of description and should not be regarded as limiting.</p><p id="p-0051" num="0050">Insulin-containing infant feeds are known in the art and have been suggested for treatment of malabsorption in preterm infants.</p><p id="p-0052" num="0051">While conducting experiments with various insulin formulations intended for use in infant feeds such as maternal milk or formulas, the present inventors have observed that when solubilized in infant feed, insulin exhibits the tendency to polymerize and agglomerate thus reducing the availability of insulin in the resultant feed formula. While vigorous mixing of the infant feed can partially resolve this problem, the present inventors postulated that this is a less than optimal solution and set out to improve insulin solubility in infant feed.</p><p id="p-0053" num="0052">Thus, according to one aspect of the present invention there is provided and insulin formulation that is readily dissolvable in an infant feed (e.g., maternal milk or formula) and exhibits stability (structural and functional) in the feed without agglomeration for extended periods of time.</p><p id="p-0054" num="0053">The present preparation includes insulin (e.g., human recombinant), a carbohydrate (e.g., oligosaccharide such as maltodextrin) and sodium chloride at a ratio of 1:A:B (w:w:w respectively), wherein ranges of A and B are 1000-100,000 and 10-50, respectively. One gram of the insulin formulation can include 2-40 IU. The insulin formulation can further include cyclodextrin at a ratio of 10-1000 with respect to the insulin. Carbohydrates such as, for example, monosaccharides (e.g. glucose), disaccharides (e.g. lactose, maltose), oligosaccharides (dextrins (e.g. Maltodextrin), cyclodextrins (e.g. Hydroxypropyl-beta-cyclodextrin (HPbCD) and polysaccharides are used as stabilizers, fillers and cryoprotectants. Buffering agents (e.g. sodium or potassium phosphate salts) can also be added to the composition.</p><p id="p-0055" num="0054">The formulation can be combined with an oil-in-water nanoemulsion having nanodroplets that include the Docosahexaenoic acid (DHA) and coenzyme Q10.</p><p id="p-0056" num="0055">The formulation can be in powder form and when reconstituted in deionized water or 0.9% sodium chloride solution at concentration of 0.03 g/ml can exhibit a pH of 6.0-7.6.</p><p id="p-0057" num="0056">The present inventors have discovered that pretreatment of insulin at pH 6.9-8.0, compounding with a carbohydrate at pH 6.7-7.6 and lyophilization, results in an amorphous insulin powder (<figref idref="DRAWINGS">FIG. <b>8</b></figref>) that is freely soluble in human breast milk and thus overcomes the aforementioned limitations of prior art insulin formulations.</p><p id="p-0058" num="0057">The present insulin formulation is an amorphous powder in which insulin is incorporated into an amorphous structure mainly composed of a filler (e.g. maltodextrin). The water content of the preparation can be 6.5% or lower, the osmolarity is about 110-120 mosm/kg when reconstituted in deionized water at concentration of 0.1 g/ml and the pH is 6.0-7.6 when reconstituted in deionized water or 0.9% sodium chloride solution at concentration of 0.03 g/ml. Typical thermogram curves, obtained by thermogravimetric analysis (TGA) and Differential scanning calorimetry (DSC), are shown in <figref idref="DRAWINGS">FIGS. <b>9</b>-<b>10</b></figref>. Solid-state NMR spectrum of a formulation of the present, invention is provided in <figref idref="DRAWINGS">FIG. <b>11</b></figref>.</p><p id="p-0059" num="0058">As is mentioned herein, the present insulin formulation can be added as a powder (or liquid) to an infant feed such as, for example, human milk. The human milk be mother breast milk or donor breast milk fresh and homogenized.</p><p id="p-0060" num="0059">When in powder form, the present insulin formulation can be reconstituted in an infant feed to a final insulin concentration of 0.1-8 IU/ml.</p><p id="p-0061" num="0060">The present formulation can be packaged as a powder and stored for extended time periods (days/months).</p><p id="p-0062" num="0061">The package can be, for example, a glass vial or an aluminum sachet filled with a dry form of the present formulation. The pack can include 0.1-1.0 grams of a powder form of the formulation with each gram including 0.2-40 IU insulin. The headspace of the packaging unit can be air or inert gas (e.g. nitrogen).</p><p id="p-0063" num="0062">The package can provide a moisture and/or oxygen barrier with a moisture vapor transmission rate (MVTR) of less than about 0.1 g/m<sup>2</sup>/24 h and an oxygen transmission rate (OTR) of less than about 0.1 cm<sup>3</sup>/m<sup>2</sup>/24 h.</p><p id="p-0064" num="0063">When packaged as disclosed herein, the present formulation is highly stable and can be stored for prolonged periods with insulin activity decreasing by no more than about 1-10%, when stored at between about 2&#xb0; C. to about 8&#xb0; C. for up to 24 months. Additionally, the water content of the packaged formulation is typically no more than about 4.5-6.5% by weight when stored at between about 2&#xb0; C. to about 8&#xb0; C. for 24 months.</p><p id="p-0065" num="0064">The insulin formulation can be reconstituted in deionized water or 0.9% sodium chloride solution and the resulting solution can be added to an infant feed (Mother's Own Milk, Donor Breast Milk, Formula etc.) to provide the concentration of insulin described above for the powdered formulation.</p><p id="p-0066" num="0065">As is described herein and demonstrated in the Examples section, the present insulin formulation and feed containing same can be used to accelerate wean-off of pre-term infants from parenteral nutrition and to substantially reduce adverse events overall, as well as specific conditions of interest including necrotizing colitis (NEC) and late onset sepsis (LOS).</p><p id="p-0067" num="0066">Thus, according to another aspect of the present invention there is provided a method of preventing or reducing the risk and severity of, LOS in a subject in need such as a preterm infant. The method is effected by administering a therapeutically effective amount of the infant feed mixed with the drug of the present invention to the subject in need. Such administration can be oral or through a feeding tube.</p><p id="p-0068" num="0067">Thus, according to yet another aspect of the present invention there is provided a method of preventing or reducing the risk and severity of, NEC in a subject in need such as a preterm infant. The method is effected by administering a therapeutically effective amount of the infant feed mixed with the drug of the present invention to the subject in need. Such administration can be oral or through a feeding tube.</p><p id="p-0069" num="0068">The term &#x201c;therapeutically effective amount&#x201d; denotes a dose of an active ingredient or a feed comprising the active ingredient that will provide the therapeutic effect for which the active ingredient is indicated.</p><p id="p-0070" num="0069">As used herein the phrase &#x201c;subject in need thereof&#x201d; refers to a human infant. The human infant can be at any age (e.g., a term or preterm infant) or of any gender. The subject in need can be a preterm infant born at a gestational age of 24 to 37 weeks or a low-birth-weight full term infant or an Intrauterine growth restriction (IUGR) infant or Small for Gestational Age infant.</p><p id="p-0071" num="0070">A typical dose regimen established by the present inventors can be administered via continuous enteral administration or bolus intake using 0.1-1 gm of powder mixed into 1-3 ml of an infant feed divided into 1-12 oral administrations a day for example.</p><p id="p-0072" num="0071">As is described in the Examples section that follows, the present regimen resulted in less NEC cases in the 0.3 IU/kg/day dose group compared to placebo; Necrotizing enterocolitis (Bell stage 2 or 3) occurred in 7 infants (6%) in the low-dose group, 4 infants (5%) in the high-dose group, and 10 infants (10%) in the placebo group. When observing the most fragile population (26-28 weeks gestational age strata) the difference is even more pronounced&#x2014;4.3% of subjects in treatment group had NEC vs. 19.6% in the placebo group. There was a meaningful difference between groups in the percentage of infants experiencing infections (including sepsis and other infections). When observing the entire study population, the general incidence was 30% in the 0.06 IU/kg/day dose group, 34.7% in the 0.3 IU/kg/day dose group and 42.9% in the Placebo group.</p><p id="p-0073" num="0072">A simultaneous assessment of intestinal permeability and lactase activity by sugar absorption test (SAT) performed in another study using the present regimen showed a trend towards lower intestinal permeability (indicating rapid maturation of the GI) and higher lactase activity in the treatment groups.</p><p id="p-0074" num="0073">The efficacy of the present study is also demonstrated by the time to discharge (to home or secondary site) as is demonstrated by the results shown in Example 4. As is shown therein, a reduction of time to discharge from primary care of a preterm infant is by at least 5% as compared to an untreated preterm infant (control). This translates to discharge that is at least 5 days earlier than that expected.</p><p id="p-0075" num="0074">Another study was performed aimed to assess the efficacy of 2 doses of enteral insulin administration compared to placebo with respect to early differences in intestinal microbiota. This study showed significant differences in GI microbiota between the treatment groups and placebo. At the end of treatment, high insulin dose showed less microbial diversity than placebo (p=0.0192). Insulin increases Firmicutes phylum and decreases Proteobacteria phylum. Enteral insulin administration had a reduction in Proteobacteria and an increase in Firmicutes and Clostridiaceae. These results indicate that the present formulation and regimen facilitate rapid maturation of gut microbiota. Decrease of Proteobacteria and increase of Firmicutes obtained in this study are the changes observed previously in low risk infants for NEC.</p><p id="p-0076" num="0075">As used herein the term &#x201c;about&#x201d; refers to &#xb1;10%.</p><p id="p-0077" num="0076">Additional objects, advantages, and novel features of the present invention will become apparent to one ordinarily skilled in the art upon examination of the following examples, which are not intended to be limiting.</p><heading id="h-0006" level="1">EXAMPLES</heading><p id="p-0078" num="0077">Reference is now made to the following examples, which together with the above descriptions, illustrate the invention in a non-limiting fashion.</p><heading id="h-0007" level="1">Example 1</heading><heading id="h-0008" level="1">Insulin and Infant Feed Formulations</heading><p id="p-0079" num="0078">Insulin formulations were prepared and tested (in an infant feed) for effectiveness in treating preterm infants.</p><heading id="h-0009" level="2">Formulation I</heading><p id="p-0080" num="0079">Insulin as active ingredient, sodium chloride as solubilizing agent and oligosaccharide as filler and stabilizer (e.g. Maltodextrin). The finished product is a lyophilized powder packed in glass vials. Strength of the reconstituted solution is regulated by the diluent volume.</p><p id="p-0081" num="0000"><tables id="TABLE-US-00001" num="00001"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="119pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 1</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Content per</entry></row><row><entry/><entry>Ingredient</entry><entry>unit dose (vial)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="70pt" align="right"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Recombinant Human </entry><entry>0.04-0.05 </entry><entry>mg</entry></row><row><entry/><entry>Insulin (rh-Insulin)</entry><entry>(1-1.5 </entry><entry>IU)</entry></row><row><entry/><entry>Maltodextrin</entry><entry>100-500 </entry><entry>mg</entry></row><row><entry/><entry>Sodium Chloride</entry><entry>1.0-2.0 </entry><entry>mg</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0010" level="2">Materials and Methods</heading><p id="p-0082" num="0080">A solution of rh-Insulin, 24.5 IU/ml, was prepared as follows: 13 mg Insulin were solubilized in 1 ml 0.1N hydrochloric acid, diluted up to 15 ml with water and the pH was adjusted to 7.6 with 0.1N sodium hydroxide.</p><heading id="h-0011" level="2">Formulation Compounding:</heading><p id="p-0083" num="0081">Forty grams of maltodextrin were dissolved in 100 ml water and pH of the obtained solution was adjusted to 7.2. 2 ml of 6% sodium chloride solution and 4 ml of Insulin solution were added to the formulation mixture, the pH was adjusted to 7.0.</p><p id="p-0084" num="0000">The resulting bulk was filtered through 0.22 um PES membrane, filled into the glass vials (filling volume 1.7 ml) and lyophilized.</p><p id="p-0085" num="0082">Each vial with lyophilized powder contained 1.25 IU rh-Insulin, 510 mg maltodextrin and 1.5 mg sodium chloride.</p><heading id="h-0012" level="2">Formulation II</heading><p id="p-0086" num="0083">Insulin as active ingredient, cyclodextrin as encapsulating agent (e.g. Hydroxypropyl Beta-Cyclodextrin), sodium chloride as solubilizing agent and oligosaccharide as filler and stabilizer (e.g. Maltodextrin). The finished product is a lyophilized powder packed in glass vials. Strength of the reconstituted solution is regulated by the diluent volume.</p><p id="p-0087" num="0000"><tables id="TABLE-US-00002" num="00002"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="91pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 2</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Content per</entry></row><row><entry/><entry>Ingredient</entry><entry>unit dose (vial)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="56pt" align="right"/><colspec colname="3" colwidth="35pt" align="left"/><tbody valign="top"><row><entry/><entry>Recombinant Human Insulin (rh-</entry><entry>0.04-0.05 </entry><entry>mg</entry></row><row><entry/><entry>Insulin)</entry><entry>(1-1.5 </entry><entry>IU)</entry></row><row><entry/><entry>Hydroxypropyl Beta-Cyclodextrin</entry><entry>2.0 </entry><entry>mg</entry></row><row><entry/><entry>Maltodextrin</entry><entry>100 </entry><entry>mg</entry></row><row><entry/><entry>Sodium Chloride</entry><entry>1.0 </entry><entry>mg</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0013" level="2">Materials and Methods</heading><p id="p-0088" num="0084">A solution of rh-Insulin, 62 IU/ml, was prepared as follows: 85.6 mg Insulin were solubilized in 5 ml 0.1N hydrochloric acid, diluted with 30 ml water and the pH was adjusted to 7.2 with 0.1N sodium hydroxide.</p><heading id="h-0014" level="2">Formulation Compounding:</heading><p id="p-0089" num="0085">Two hundred grams of maltodextrin were dissolved in 600 g water and pH of the obtained solution was adjusted to 7.3. 2 g of sodium chloride, pre-dissolved in 60 ml water, and Insulin solution were added to the formulation mixture, the pH was adjusted to 7.0 and additional portion of water was added to complete the bulk volume to 1 L.</p><p id="p-0090" num="0086">The resulting bulk was filtered through 0.22 um PES membrane, filled into the glass vials (filling volume 0.5 ml) and lyophilized.</p><p id="p-0091" num="0000">Each vial with lyophilized powder contained 1.2 IU rh-Insulin, 100 mg maltodextrin and 1.0 mg sodium chloride.</p><heading id="h-0015" level="2">Formulation III</heading><p id="p-0092" num="0087">A solution of rh-Insulin, 243 IU/ml, was prepared as follows: 84.4 mg Insulin were solubilized in 1 ml 0.1N hydrochloric acid, diluted up to 10 ml with water and the pH was adjusted to 8.1 with 0.1N sodium hydroxide.</p><heading id="h-0016" level="2">Formulation Compounding:</heading><p id="p-0093" num="0088">Thirty grams of maltodextrin were dissolved in 60 ml water and pH of the obtained solution was adjusted to 7.1. 2.7 ml of 7.5% sodium chloride solution and 1 ml of Insulin solution were added to the formulation mixture, the pH was adjusted to 7.3 and additional portion of water was added to complete the bulk weight to 100 g.</p><p id="p-0094" num="0000">The resulting bulk was filtered through 0.22 um PES membrane, filled into the glass vials (filling volume 0.5 ml) and lyophilized.</p><p id="p-0095" num="0089">Each vial with lyophilized powder contained 1.4 IU rh-Insulin, 172 mg maltodextrin and 1.2 mg sodium chloride.</p><heading id="h-0017" level="2">Formulation IV</heading><p id="p-0096" num="0090">This example describes the formulation produced at commercial scale 9 kg of the liquid bulk (0.9 kg of the lyophilized powder). Insulin as active ingredient, sodium chloride as solubilizing agent and oligosaccharide as filler and stabilizer (e.g. Maltodextrin). The finished product is a lyophilized powder packed in glass vials. Strength of the reconstituted solution is regulated by the diluent volume.</p><p id="p-0097" num="0000"><tables id="TABLE-US-00003" num="00003"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="119pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 3</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Content per</entry></row><row><entry/><entry>Ingredient</entry><entry>unit dose (vial)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="35pt" align="left"/><colspec colname="1" colwidth="63pt" align="left"/><colspec colname="2" colwidth="63pt" align="right"/><colspec colname="3" colwidth="56pt" align="left"/><tbody valign="top"><row><entry/><entry>Recombinant Human </entry><entry>0.035 </entry><entry>mg</entry></row><row><entry/><entry>Insulin (rh-Insulin)</entry><entry>(1 </entry><entry>IU)</entry></row><row><entry/><entry>Maltodextrin</entry><entry>99 </entry><entry>mg</entry></row><row><entry/><entry>Sodium Chloride</entry><entry>1 </entry><entry>mg</entry></row><row><entry/><entry>Total weight</entry><entry>100 </entry><entry>mg</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0018" level="2">Materials and Methods</heading><p id="p-0098" num="0091">A solution of rh-Insulin, 33 IU/ml, was prepared as follows: 0.39 g Insulin were solubilized in 20 g 0.1N hydrochloric acid, diluted with 300 g water for injection and then neutralized with 20 g of 0.1N sodium hydroxide. The pH was adjusted to 7.2 with 0.1N sodium hydroxide.</p><heading id="h-0019" level="2">Formulation Compounding:</heading><p id="p-0099" num="0092">856 grams of maltodextrin and 8.6 gram of sodium chloride were dissolved in 6854-gram water and pH of the obtained solution was adjusted to 7.2. The insulin solution was added to the compounding mixture, the weight of the resulting formulation was adjusted up to 9.0 kg and the pH was adjusted to 7.0.</p><p id="p-0100" num="0093">The resulting bulk was filtered through 0.22 um PES membrane, filled into the glass vials (filling volume 1 g) and lyophilized.</p><p id="p-0101" num="0094">Each vial with lyophilized powder contained HU rh-Insulin, 99 mg maltodextrin and 1 mg sodium chloride.</p><p id="p-0102" num="0000">Analytical characteristics of the obtained dry powder are: content of Insulin (insulin+A21 desamido insulin) is 1.13 IU/vial, content of A21 desamido insulin is 0.5% (by area percent), content of other total related substances is 0.1% (by area percent), relative standard deviation of insulin content per vial (uniformity) is 0.9%, water content is 0.8%, pH is 6.7, reconstitution time of the powder in water is below 5 minutes.</p><heading id="h-0020" level="2">Formulation V</heading><p id="p-0103" num="0095">This formulation was produced by forming a DHA and Coenzyme Q10 emulsion using a solvent displacement method, adding rh-Insulin and cryoprotectant (e.g. dextrins, cyclodextrins), filtrating and lyophilizing.</p><p id="p-0104" num="0000"><tables id="TABLE-US-00004" num="00004"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 4</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Content per unit </entry></row><row><entry/><entry>Ingredient</entry><entry>dose (vial)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="49pt" align="right"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Recombinant Human </entry><entry>0.04 </entry><entry>mg</entry></row><row><entry/><entry>Insulin (rh-Insulin)</entry><entry>(1.2 </entry><entry>IU)</entry></row><row><entry/><entry>Cis-4,7,10,13,16,19- </entry><entry>2.5 </entry><entry>mg</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><tbody valign="top"><row><entry/><entry>Docosahexaenoic acid (DHA)</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="49pt" align="right"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Coenzyme Q10 (CoQ10)</entry><entry>1.1 </entry><entry>mg</entry></row><row><entry/><entry>Tyloxapol</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Lipoid E 80</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Polyvinyl alcohol (PVA)</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Maltodextrin</entry><entry>33 </entry><entry>mg</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="28pt" align="left"/><colspec colname="1" colwidth="91pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><tbody valign="top"><row><entry/><entry>Sodium hydroxide*</entry><entry>&#x2014;</entry></row><row><entry/><entry>Hydrochloric acid*</entry><entry>&#x2014;</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry namest="offset" nameend="2" align="left" id="FOO-00001">*Sodium hydroxide or hydrochloric acid are used for adjusting the pH value and not included in the sum.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0021" level="2">Materials and Methods</heading><p id="p-0105" num="0096">A solution of rh-Insulin, 40 IU/ml, was prepared as follows: 27.5 mg Insulin were solubilized in 2 ml 0.1N hydrochloric acid, diluted with 18 ml water and the pH was adjusted to 7.2 with 0.1N sodium hydroxide.</p><p id="p-0106" num="0097">An oil in water nanoemulsion (average droplet size 120 nm) was prepared as follows: 690 mg of Coenzyme Q10, 1533 mg of DHA ethyl ester, 300 mg Tyloxapol and 300 mg Lipoid E80 were dissolved in 56 ml Ethanol. The mixture was added dropwise through 21 G needle to 300 ml of 0.1% PVA aqueous solution continuously mixed at 350 RPM at room temperature. Resulting emulsion was mixed for additional 10 minutes, diluted with 0.1% PVA solution and the organic solvents were removed via tangential flow filtration using Hydrosart, MWCO 30,000 membrane.</p><p id="p-0107" num="0098">Ten grams of maltodextrin were dissolved in 160 ml of the obtained emulsion and then mixed with Insulin solution. The volume of the final bulk was completed to 300 ml and the pH was adjusted to 6.9. The emulsion was filtered through 0.22 um PES membrane, filled into glass vials (filling volume 1 ml/vial) and lyophilized. Each vial contains 1.2 IU rh-Insulin, 2.5 mg DHA and 1.1 mg Coenzyme Q10. The average size of the droplet particles in the reconstituted powder is 295 nm.</p><heading id="h-0022" level="2">Formulation VI</heading><p id="p-0108" num="0099">Formulation steps are identical to those of formulation V.</p><p id="p-0109" num="0000"><tables id="TABLE-US-00005" num="00005"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><thead><row><entry/><entry namest="offset" nameend="2" rowsep="1">TABLE 5</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry/><entry>Content per unit </entry></row><row><entry/><entry>Ingredient</entry><entry>dose (vial)</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="49pt" align="right"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Recombinant Human </entry><entry>0.04 </entry><entry>mg</entry></row><row><entry/><entry>Insulin (rh-Insulin)</entry><entry>(1.2 </entry><entry>IU)</entry></row><row><entry/><entry>Cis-4,7,10,13,16,19- </entry><entry>2.3 </entry><entry>mg</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><tbody valign="top"><row><entry/><entry>Docosahexaenoic acid (DHA)</entry><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="49pt" align="right"/><colspec colname="3" colwidth="49pt" align="left"/><tbody valign="top"><row><entry/><entry>Coenzyme Q10 (CoQ10)</entry><entry>1.1 </entry><entry>mg</entry></row><row><entry/><entry>Tyloxapol</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Lipoid E 80</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Polyvinyl alcohol (PVA)</entry><entry>0.5 </entry><entry>mg</entry></row><row><entry/><entry>Hydroxypropyl Beta Cyclodextrin</entry><entry>30 </entry><entry>mg</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="offset" colwidth="21pt" align="left"/><colspec colname="1" colwidth="98pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><tbody valign="top"><row><entry/><entry>Sodium hydroxide*</entry><entry>&#x2014;</entry></row><row><entry/><entry>Hydrochloric acid*</entry><entry>&#x2014;</entry></row><row><entry/><entry namest="offset" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry namest="offset" nameend="2" align="left" id="FOO-00002">*Sodium hydroxide or hydrochloric acid are used for adjusting the pH value and not included in the sum.</entry></row></tbody></tgroup></table></tables></p><heading id="h-0023" level="2">Materials and Methods</heading><p id="p-0110" num="0100">A solution of rh-Insulin, 40 IU/ml, was prepared as follows: 27.2 mg Insulin were solubilized in 2 ml 0.1N hydrochloric acid, diluted with 18 ml water and the pH was adjusted to 7.2 with 0.1N sodium hydroxide.</p><p id="p-0111" num="0000">An oil in water nanoemulsion (average droplet size 120 nm) was prepared as described for formulation IV.</p><p id="p-0112" num="0101">Ten grams of Hydroxypropyl Beta Cyclodextrin were dissolved in 160 ml of the obtained emulsion and then mixed with Insulin solution. The volume of the final bulk was completed to 327 ml and the pH was adjusted to 6.9. The emulsion was filtered through 0.22 um PES membrane, filled into glass vials (filling volume 1 ml/vial) and lyophilized. Each vial contains 1.2 IU rh-Insulin, 2.5 mg DHA and 1.1 mg Coenzyme Q10. The average size of the droplet particles in the reconstituted powder is 143 nm.</p><heading id="h-0024" level="1">Example 2</heading><heading id="h-0025" level="1">Testing of Formulations I-IV</heading><p id="p-0113" num="0102">The content of rh-Insulin was determined by reverse-phase high performance liquid chromatography method on Hypersil Gold-C18 column (3&#xd7;50 mm, 3 &#x3bc;m) and gradient elution with a mobile phase composed of aqueous and organic phases (acetonitrile) acidified with 0.1% trifluoroacetic acid (TFA). Flow rate&#x2014;0.3 ml/min, UV detection at 205 nm. A typical chromatogram of formulations I-IV is shown in <figref idref="DRAWINGS">FIG. <b>1</b></figref>.</p><heading id="h-0026" level="1">Testing of Formulations V-VI</heading><p id="p-0114" num="0103">The content of rh-Insulin, DHA and Coenzyme Q10 was determined by reverse-phase high performance liquid chromatography method on Hypersil Gold-C18 column (3&#xd7;50 mm, 3 &#x3bc;m) and gradient elution with a mobile phase composed of aqueous and organic phases (mixture of acetonitrile:methanol:2-propanol 75:15:10) acidified with 0.1% trifluoroacetic acid (TFA). Flow rate&#x2014;0.6 ml/min, UV detection at 205 nm for Insulin and 214 nm for DHA and Coenzyme Q10. A typical chromatogram of formulations V-VI is shown in <figref idref="DRAWINGS">FIG. <b>2</b></figref>. A typical chromatogram of DHA and Coenzyme Q10 determination in formulations V-VI is shown in <figref idref="DRAWINGS">FIG. <b>3</b></figref>.</p><heading id="h-0027" level="1">Example 3</heading><heading id="h-0028" level="1">Infant Feed Solubility</heading><p id="p-0115" num="0104">A study was designed to assess solubility of the present formulation at a pH range of human breast milk. Three dry samples, containing maltodextrin, sodium chloride and insulin (1 IU) were prepared as follows.</p><p id="p-0116" num="0105">Sample 1 is a crystalline, thermally dried powder, prepared by spraying a solution of maltodextrin, sodium chloride and insulin onto solid maltodextrin particles and subsequent drying at 35&#xb0; C. Dried powder was mixed 1:3 with maltodextrin, the final pH was 6.3.</p><p id="p-0117" num="0106">Sample 2 is one variant of the present formulation, presented as an amorphous powder, at pH 7.0, prepared as described in Example 1, Formulations I-III.</p><p id="p-0118" num="0107">Sample 3 is a physical mixture of dry ingredients (maltodextrin, sodium chloride and insulin), dry blended without any pretreatment.</p><p id="p-0119" num="0108">A certain amount of each formulation (equivalent to 1 IU of insulin) was reconstituted in 1.8 ml of 0.1M phosphate buffer at pH 6.3, 6.7 and 7.2 and visually examined.</p><p id="p-0120" num="0109">The results show that Sample 2 (the present formulation) dissolves freely in the wide pH range of breast milk (6.3-7.2), resulting in a clear solution comparable to the reference buffer. Sample 1 (thermally dried formulation) and Sample 3 (physical blend of dry ingredients, no pretreatment) were partially soluble in the tested pH range, resulting in a cloudy solution.</p><p id="p-0121" num="0110">The dissolution profile of the test samples was evaluated using HPLC in the following media:</p><p id="p-0122" num="0111">0.01 N. HCl, double deionized water and 0.1 M phosphate buffer at pH 6.3 and 7.4.</p><p id="p-0123" num="0112">For each sample, the percentage of dissolution in water and phosphate buffer was calculated relative to the amount of insulin determined in 0.01 N. HCl. The dissolution results obtained (Table 6 below) indicate that the present composition is highly soluble in the pH range of infant formula.</p><p id="p-0124" num="0000"><tables id="TABLE-US-00006" num="00006"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="2"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="140pt" align="center"/><thead><row><entry namest="1" nameend="2" rowsep="1">TABLE 6</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="2" align="center" rowsep="1"/></row><row><entry/><entry>% Dissolution of Insulin</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="77pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="49pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry/><entry>Sample 3</entry></row><row><entry/><entry/><entry>Sample 2-</entry><entry>(physical blend</entry></row><row><entry/><entry>Sample 1</entry><entry>present</entry><entry>of dry</entry></row><row><entry/><entry>(thermal</entry><entry>formulation</entry><entry>ingredients, no</entry></row><row><entry>Dissolution medium</entry><entry>drying)</entry><entry>(freeze drying)</entry><entry>pre-treatment)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry>0.01 N HCl</entry><entry>100.0%</entry><entry>100.0%</entry><entry>&#x2009;100%</entry></row><row><entry>Double deionized water</entry><entry>&#x2002;84.0%</entry><entry>&#x2002;93.1%</entry><entry>68.1%</entry></row><row><entry>0.1 M Phosphate buffer, </entry><entry>&#x2002;78.9%</entry><entry>&#x2002;93.3%</entry><entry>81.8%</entry></row><row><entry>pH 6.3</entry><entry/><entry/><entry/></row><row><entry>0.1 M Phosphate buffer, </entry><entry>&#x2002;84.3%</entry><entry>&#x2002;93.6%</entry><entry>95.0%</entry></row><row><entry>pH 7.4</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0125" num="0113">In addition, samples 1 and 2 were reconstituted in cow's milk (pH 6.89, fat content 3%). The results were consistent with observations of the buffer recovery test. Sample 1 is partially reconstituted in milk, resulting in visible clots that can adhere or block the passage of the reconstituted drug through the nasogastric tube. Sample 2 is completely reconstituted in milk, resulting in a homogeneous mixture.</p><heading id="h-0029" level="1">Example 4</heading><heading id="h-0030" level="1">Pre-Term Infant Study&#x2014;Efficacy</heading><p id="p-0126" num="0114">A study was designed to assess the efficacy and safety of an enteral rh-insulin formulation in preterm infants. Following screening procedures, eligible infants born between 26 and up to 32 weeks of pregnancy and weighing at least 500 g at birth were to be randomly assigned to 1 of the 3 treatment groups in a 1:1:1 ratio.</p><p id="p-0127" num="0115">Treatment commenced at postnatal age of at least 6 hours through and including 120 hours post birth. The treatment period for infants who were fed solely on own mother's milk (OMM) commenced within the first 72 hours post birth.</p><p id="p-0128" num="0116">The treatment period was defined as the first day of dosing (Day 1) for up to 28 days or until discharge from primary hospital, if prior to Day 28.</p><p id="p-0129" num="0117">The tested formulation was administered at 0.3 IU/Kg/Day for up to 28 days. Prior to administration, the powder was reconstituted mostly in human breast milk, donor breast milk, saline or half saline.</p><heading id="h-0031" level="2">Results</heading><p id="p-0130" num="0118">Infants were discharged to either home or to secondary site from primary hospital. When analyzing time to discharge, two analyses are presented: 1) analysis of discharge from primary recruiting hospital (separate comparisons of subjects transferring to secondary hospital and subjects discharged home); and 2) discharge to home (either from primary or secondary hospital).</p><p id="p-0131" num="0000">Time to Discharge from Primary Hospital</p><p id="p-0132" num="0119">Infants were discharged from primary hospital to either home or to a secondary hospital, depending mostly on region. Each infant in the ITT analysis had one destination for analysis, by that each arm and strata were compared. Both treatment arms had significantly shorter time to discharge compared to placebo, demonstrating faster time to stable well-being.</p><p id="p-0133" num="0120">The Median number of days to discharge from hospital (to either home or secondary hospital) was lowest in the insulin formulation comprising 0.3 IU/Kg group [median=42.0 days, P=0.055], followed by the Insulin formulation comprising 0.0406 IU/Kg group [median=43.0 days, p=0.04*] compared to placebo [median=49.5 days].</p><heading id="h-0032" level="2">Time to Discharge to a Secondary Site</heading><p id="p-0134" num="0121">Some hospitals discharge infants to secondary sites after infants stabilize and are out of immediate life threatening condition. Infants are discharged to secondary sites and several weeks later&#x2014;to home. In the trial, subjects in the Insulin formulation comprising 0.3 IU/Kg group were discharged earlier than patients in the placebo group to a secondary site&#x2014;as indicated by the medians and difference from placebo (Table 7 below).</p><p id="p-0135" num="0000"><tables id="TABLE-US-00007" num="00007"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 7</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Number of Days to Discharge from Primary Hospital </entry></row><row><entry>to a Secondary Site by Gestation Age - Full Analysis Set</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="126pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Treatment</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="28pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Enteral rh-</entry><entry>Enteral rh-</entry><entry/></row><row><entry/><entry/><entry>insulin</entry><entry>insulin</entry><entry/></row><row><entry/><entry/><entry>formulation</entry><entry>formulation</entry><entry/></row><row><entry>Gestation</entry><entry/><entry>0.06 IU/kg/day</entry><entry>0.3 IU/kg/day</entry><entry>Placebo</entry></row><row><entry>Age Group</entry><entry>Statistic</entry><entry>(N = 108)</entry><entry>(N = 94)</entry><entry>(N = 98)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="42pt" align="center"/><colspec colname="3" colwidth="56pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>26 - 28 weeks</entry><entry>n</entry><entry>14</entry><entry>16</entry><entry>14</entry></row><row><entry/><entry>Median</entry><entry>34.0</entry><entry>31.5</entry><entry>39.0</entry></row><row><entry/><entry>Difference </entry><entry>3.5</entry><entry>5.3</entry><entry>&#x2014;</entry></row><row><entry/><entry>from placebo</entry><entry/><entry/><entry/></row><row><entry>29 - 32 weeks</entry><entry>n</entry><entry>8</entry><entry>5</entry><entry>12</entry></row><row><entry/><entry>Median</entry><entry>22.0</entry><entry>11.0</entry><entry>23.0</entry></row><row><entry/><entry>Difference </entry><entry>&#x2212;2.3</entry><entry>9.0</entry><entry>&#x2014;</entry></row><row><entry/><entry>from placebo</entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0033" level="2">Time to Discharge to Home</heading><p id="p-0136" num="0122">Another type of analysis performed assessed the time to discharge home for all infants, regardless of if the discharge was directly from primary hospital or followed a secondary site/unit. This analysis showed a similar trend for reduction in time to discharge, however showed much larger variability compared to the main analysis &#x2018;discharge from primary hospital&#x2019;.</p><p id="p-0137" num="0123">Relative to placebo, treatment with Insulin formulation comprising 0.06 IU/Kg resulted in significantly fewer days to discharge to home [median=48.0 days vs median=60.0 days in placebo, P=0.025*]. Treatment with Insulin formulation comprising 0.3 IU/Kg resulted in a median of 55.0 days to discharge to home [p=0.27 versus placebo].</p><p id="p-0138" num="0124">When analyzing both treatment arms together, treatment groups discharge was earlier [median=52 days, p=0.046] compared to placebo [median=60 days].</p><heading id="h-0034" level="2">Time to Wean-Off PN</heading><p id="p-0139" num="0125">A statistically significant difference in time to weaning off parenteral nutrition (PN) was observed in the group fed an insulin-supplemented feed at a concentration of 0.3 IU/kg/day compared to placebo (<b>6</b> vs. 8 days, p=0.0096**).</p><p id="p-0140" num="0126">In assessing the time to wean-off PN by gestation age group, in the older population (29-32 weeks) time to weaning off PN was also shorter in the 0.3 IU/kg/day group (<b>4</b> vs. 6 days). The results are summarized in Tables 8-10 below and graphically presented in <figref idref="DRAWINGS">FIG. <b>4</b></figref> which shows the Probability of PN wean-off per group (Kaplan-Meier survival curve).</p><p id="p-0141" num="0000"><tables id="TABLE-US-00008" num="00008"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 8</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Analysis Summary of Number of Days </entry></row><row><entry>to Wean-off PN- Full Analysis Set</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="42pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Enteral rh- </entry><entry>Enteral rh- </entry><entry/></row><row><entry/><entry/><entry>insulin</entry><entry>insulin</entry><entry/></row><row><entry>Gestation</entry><entry/><entry>formulation</entry><entry>formulation</entry><entry/></row><row><entry>Age</entry><entry/><entry>0.06 IU/kg/day</entry><entry>0.3 IU/kg/day</entry><entry>Placebo</entry></row><row><entry>Group</entry><entry>Statistics</entry><entry>(N = 108)</entry><entry>(N = 94)</entry><entry>(N = 98)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="42pt" align="char" char="."/><tbody valign="top"><row><entry>All</entry><entry>n (%)</entry><entry>107</entry><entry>92</entry><entry>97</entry></row><row><entry/><entry>Median</entry><entry>7.0</entry><entry>6.0</entry><entry>8.0</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0142" num="0000"><tables id="TABLE-US-00009" num="00009"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 9</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Analysis Summary of Number of Days </entry></row><row><entry>to Wean-off PN- Full Analysis Set</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="77pt" align="center"/><colspec colname="3" colwidth="84pt" align="center"/><tbody valign="top"><row><entry/><entry>Gestation</entry><entry>Treatment</entry><entry>Stratified Van Elteren</entry></row><row><entry/><entry>Age Group</entry><entry>Comparison</entry><entry>Test p-value</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="offset" colwidth="14pt" align="left"/><colspec colname="1" colwidth="42pt" align="left"/><colspec colname="2" colwidth="77pt" align="center"/><colspec colname="3" colwidth="84pt" align="char" char="."/><tbody valign="top"><row><entry/><entry>All</entry><entry>Enteral rh- </entry><entry>0.48</entry></row><row><entry/><entry/><entry>insulin formulation</entry><entry/></row><row><entry/><entry/><entry>0.06 IU/kg/day (N = 107) </entry><entry/></row><row><entry/><entry/><entry>vs. Placebo (N = 97)</entry><entry/></row><row><entry/><entry/><entry>Enteral rh- </entry><entry>0.0096**</entry></row><row><entry/><entry/><entry>insulin formulation</entry><entry/></row><row><entry/><entry/><entry>0.3 IU/kg/day (N = 92) </entry><entry/></row><row><entry/><entry/><entry>vs. Placebo (N = 97)</entry></row><row><entry/><entry namest="offset" nameend="3" align="center" rowsep="1"/></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00003">Note:</entry></row><row><entry/><entry namest="offset" nameend="3" align="left" id="FOO-00004">stratification factor: gestation age group (26-28 weeks, 29-32 weeks)</entry></row></tbody></tgroup></table></tables></p><p id="p-0143" num="0000"><tables id="TABLE-US-00010" num="00010"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 10</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Analysis Summary of Number of Days to </entry></row><row><entry>Wean-off PN by Gestation Age - Full Analysis Set</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="center"/><colspec colname="4" colwidth="42pt" align="center"/><colspec colname="5" colwidth="35pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Enteral rh- </entry><entry>Enteral rh- </entry><entry/></row><row><entry/><entry/><entry>insulin</entry><entry>insulin</entry><entry/></row><row><entry/><entry/><entry>formulation</entry><entry>formulation</entry><entry/></row><row><entry>Gestation</entry><entry/><entry>0.06 IU/kg/day</entry><entry>0.3 IU/kg/day</entry><entry>Placebo</entry></row><row><entry>Age Group</entry><entry>Statistics</entry><entry>(N = 108)</entry><entry>(N = 94)</entry><entry>(N = 98)</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="5"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="35pt" align="center"/><colspec colname="3" colwidth="56pt" align="char" char="."/><colspec colname="4" colwidth="42pt" align="char" char="."/><colspec colname="5" colwidth="35pt" align="char" char="."/><tbody valign="top"><row><entry>26 - 28 weeks</entry><entry>n</entry><entry>48</entry><entry>59</entry><entry>51</entry></row><row><entry/><entry>Median</entry><entry>9.0</entry><entry>9.0</entry><entry>9.0</entry></row><row><entry>29 - 32 weeks</entry><entry>n</entry><entry>59</entry><entry>47</entry><entry>46</entry></row><row><entry/><entry>Median</entry><entry>6.0</entry><entry>4.0</entry><entry>6.0</entry></row><row><entry namest="1" nameend="5" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0144" num="0127">Another important endpoint for this study is the percentage of PN out of the total intake of the infant, as well as the gradual reduction in percentage of PN intake over time.</p><p id="p-0145" num="0128"><figref idref="DRAWINGS">FIG. <b>5</b></figref> shows the average PN intake per day per group, presenting a clear benefit of the treatment group, especially Enteral rh-insulin formulation 0.3 IU/kg/day compared to placebo in the rate of PN reduction out of total intake.</p><p id="p-0146" num="0129"><figref idref="DRAWINGS">FIG. <b>6</b></figref> presents the percentage of enteral nutrition out of total nutrition per group while <figref idref="DRAWINGS">FIG. <b>7</b></figref> presents the Trajectories per group.</p><heading id="h-0035" level="1">Example 5</heading><heading id="h-0036" level="1">Pre-Term Infant Study&#x2014;NEC and LOS</heading><p id="p-0147" num="0130">The study population was also observed for adverse events such as necrotizing colitis (NEC) and late onset sepsis (LOS).</p><heading id="h-0037" level="2">Necrotizing Colitis (NEC)</heading><p id="p-0148" num="0131">There was a meaningful difference between groups in the percentage of infants experiencing NEC. When observing the entire study population, general incidence was 6.3% in the 0.06 IU/kg/day dose group, 4.3% in the 0.3 IU/kg/day dose group and 10.2% in the Placebo group resulting in 60% less NEC cases in the 0.3 IU/kg/day dose group compared to placebo.</p><p id="p-0149" num="0132">When observing the younger study population (26-28 weeks GA) where NEC is more prevalent, differences becomes even more apparent 12.2% in the 0.06 IU/kg/day dose group, 4.3% in the 0.3 IU/kg/day dose group and 19.6% in the Placebo group, resulting in nearly 80% less NEC cases in 0.3 IU/kg/day dose group compared to placebo.</p><p id="p-0150" num="0133">A statistical analysis was performed which compared both the incidence and severity of NEC, using a non-parametric Kruskal-Wallis method, and showed a meaningful statistical difference in the 26-28 GA group (p=0.077). The results of this study are presented in Tables 11 and 12 below.</p><p id="p-0151" num="0000"><tables id="TABLE-US-00011" num="00011"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 11</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NEC incidence X severity distribution per group all population</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="21pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>NEC CTCAE grade</entry><entry>1</entry><entry>2</entry><entry>3</entry><entry>4</entry><entry>5</entry><entry>Total %</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>ENTERAL RH- INSULIN FORMULATION 0.06 IU/kg/day (N = 110)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>3</entry><entry>1</entry><entry>1</entry><entry>2</entry><entry>7</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>2.7%</entry><entry>0.9%</entry><entry>0.9%</entry><entry>1.8%</entry><entry>6.3%</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>ENTERAL RH- INSULIN FORMULATION 0.3 IU/kg/day (N = 95)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>0</entry><entry>2</entry><entry>1</entry><entry>1</entry><entry>4</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>0.0%</entry><entry>2.1%</entry><entry>1.1%</entry><entry>1.1%</entry><entry>4.3%</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>Placebo (N = 98)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>1</entry><entry>3</entry><entry>2</entry><entry>4</entry><entry>10</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>1.0%</entry><entry>3.1%</entry><entry>2.0%</entry><entry>4.1%</entry><entry>10.2%</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0152" num="0000"><tables id="TABLE-US-00012" num="00012"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 12</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>NEC incidence X severity distribution per group (26-28 weeks GA)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="center"/><colspec colname="3" colwidth="21pt" align="center"/><colspec colname="4" colwidth="21pt" align="center"/><colspec colname="5" colwidth="21pt" align="center"/><colspec colname="6" colwidth="21pt" align="center"/><colspec colname="7" colwidth="28pt" align="center"/><tbody valign="top"><row><entry>NEC CTCAE grade</entry><entry>1</entry><entry>2</entry><entry>3</entry><entry>4</entry><entry>5</entry><entry>Total %</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>ENTERAL RH- INSULIN FORMULATION 0.06 IU/kg/day (N = 49)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>3</entry><entry>0</entry><entry>1</entry><entry>2</entry><entry>6</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>6.1%</entry><entry>0.0%</entry><entry>2.0%</entry><entry>4.0%</entry><entry>12.2%</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>ENTERAL RH- INSULIN FORMULATION 0.3 IU/kg/day (N = 46)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>0</entry><entry>0</entry><entry>1</entry><entry>1</entry><entry>2</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>0.0%</entry><entry>0.0%</entry><entry>2.1%</entry><entry>2.1%</entry><entry>4.3%</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><tbody valign="top"><row><entry>Placebo (N = 51)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="84pt" align="left"/><colspec colname="2" colwidth="21pt" align="char" char="."/><colspec colname="3" colwidth="21pt" align="char" char="."/><colspec colname="4" colwidth="21pt" align="char" char="."/><colspec colname="5" colwidth="21pt" align="char" char="."/><colspec colname="6" colwidth="21pt" align="char" char="."/><colspec colname="7" colwidth="28pt" align="char" char="."/><tbody valign="top"><row><entry>Number of cases</entry><entry>0</entry><entry>1</entry><entry>3</entry><entry>2</entry><entry>4</entry><entry>10</entry></row><row><entry>%</entry><entry>0.0%</entry><entry>1.9%</entry><entry>5.8%</entry><entry>3.9%</entry><entry>7.8%</entry><entry>19.6%</entry></row><row><entry namest="1" nameend="7" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0153" num="0134">Poor outcome composite of occurrence of one of infections, NEC and death were calculated and compared between groups and shown in Table 13 below.</p><p id="p-0154" num="0000"><tables id="TABLE-US-00013" num="00013"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="70pt" align="center"/><colspec colname="3" colwidth="42pt" align="center"/><colspec colname="4" colwidth="35pt" align="center"/><thead><row><entry namest="1" nameend="4" rowsep="1">TABLE 13</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row><row><entry/><entry>Enteral rh- </entry><entry>Enteral rh- </entry><entry/></row><row><entry/><entry>insulin</entry><entry>insulin</entry><entry/></row><row><entry/><entry>formulation</entry><entry>formulation</entry><entry/></row><row><entry/><entry>0.06 IU/kg/day</entry><entry>0.3 IU/kg/day</entry><entry>Placebo</entry></row><row><entry>Category</entry><entry>(N = 110)</entry><entry>(N = 95)</entry><entry>(N = 98)</entry></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></thead><tbody valign="top"><row><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="right"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="14pt" align="right"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="14pt" align="right"/><colspec colname="7" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Total subjects with </entry><entry>33 </entry><entry>(30.0)</entry><entry>33 </entry><entry>(34.7)</entry><entry>42 </entry><entry>(42.9)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>infections n (%)</entry><entry/><entry/><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="right"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="14pt" align="right"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="14pt" align="right"/><colspec colname="7" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Total subjects with </entry><entry>7 </entry><entry>(6.4)</entry><entry>4 </entry><entry>(4.2)</entry><entry>9 </entry><entry>(9.2)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>NEC n (%)</entry><entry/><entry/><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="right"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="14pt" align="right"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="14pt" align="right"/><colspec colname="7" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Total subjects </entry><entry>5 </entry><entry>(4.5)</entry><entry>1</entry><entry>(1.1)</entry><entry>4</entry><entry>(4.1)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>experienced death n (%)</entry><entry/><entry/><entry/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="7"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="28pt" align="right"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="14pt" align="right"/><colspec colname="5" colwidth="28pt" align="left"/><colspec colname="6" colwidth="14pt" align="right"/><colspec colname="7" colwidth="21pt" align="left"/><tbody valign="top"><row><entry>Total subjects with any </entry><entry>38 </entry><entry>(34.5)</entry><entry>34 </entry><entry>(35.8)</entry><entry>49 </entry><entry>(50.0)</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="4"><colspec colname="1" colwidth="70pt" align="left"/><colspec colname="2" colwidth="70pt" align="left"/><colspec colname="3" colwidth="42pt" align="left"/><colspec colname="4" colwidth="35pt" align="left"/><tbody valign="top"><row><entry>event n (%)</entry><entry/><entry/><entry/></row><row><entry namest="1" nameend="4" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><p id="p-0155" num="0135">It was found that treatment groups had significantly lower percentage of subjects experiencing one of these adverse events of interest. Rates were 34.5% in enteral Rh insulin formulation 0.06 IU/kg/day dose group, 35.8% in the enteral Rh insulin formulation 0.3 IU/kg/day dose group and 50% in the Placebo group. When performing pairwise comparison of proportions&#x2014;difference between in enteral Rh insulin formulation 0.06 IU/kg/day to Placebo p=0.034, difference between enteral Rh insulin formulation 0.3 IU/kg/day to placebo p=0.065 (see Table 14 below).</p><p id="p-0156" num="0000"><tables id="TABLE-US-00014" num="00014"><table frame="none" colsep="0" rowsep="0"><tgroup align="left" colsep="0" rowsep="0" cols="1"><colspec colname="1" colwidth="217pt" align="center"/><thead><row><entry namest="1" nameend="1" rowsep="1">TABLE 14</entry></row></thead><tbody valign="top"><row><entry namest="1" nameend="1" align="center" rowsep="1"/></row><row><entry>Summary of analysis - pairwise comparison </entry></row><row><entry>of proportions of safety composite</entry></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><colspec colname="3" colwidth="70pt" align="center"/><tbody valign="top"><row><entry/><entry/><entry>Chi-squared test</entry></row><row><entry>Gestation</entry><entry/><entry>of independence</entry></row><row><entry>Age Group</entry><entry>Comparison</entry><entry>Test p-value</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup><tgroup align="left" colsep="0" rowsep="0" cols="3"><colspec colname="1" colwidth="49pt" align="left"/><colspec colname="2" colwidth="98pt" align="center"/><colspec colname="3" colwidth="70pt" align="char" char="."/><tbody valign="top"><row><entry>All</entry><entry>ENTERAL RH-INSULIN </entry><entry>0.034*</entry></row><row><entry/><entry>FORMULATION 0.06 IU/kg/day </entry><entry/></row><row><entry/><entry>(N = 110) vs. Placebo (N = 98)</entry><entry/></row><row><entry/><entry>ENTERAL RH-INSULIN </entry><entry>0.065</entry></row><row><entry/><entry>FORMULATION 0.3 IU/kg/day </entry><entry/></row><row><entry/><entry>(N = 95) vs. Placebo (N = 98)</entry></row><row><entry namest="1" nameend="3" align="center" rowsep="1"/></row></tbody></tgroup></table></tables></p><heading id="h-0038" level="2">Late Onset Sepsis (LOS)</heading><p id="p-0157" num="0136">There was a meaningful difference between groups in the percentage of infants experiencing infections (including sepsis and other infections). When observing the entire study population, the general incidence was 30% in the 0.06 IU/kg/day dose group, 34.7% in the 0.3 IU/kg/day dose group and 42.9% in the Placebo group.</p><p id="p-0158" num="0137">Specifically, when measuring the rate of clinical or culture proven sepsis, treatment groups had lower rates compared to placebo. Incidence was 12% in the 0.06 IU/kg/day dose group, 11% in the 0.3 IU/kg/day dose group and 15% in the Placebo group (almost 30% reduction in late onset sepsis incidence).</p><p id="p-0159" num="0138">It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable subcombination.</p><p id="p-0160" num="0139">Although the invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, it is intended to embrace all such alternatives, modifications and variations that fall within the spirit and broad scope of the appended claims.</p><p id="p-0161" num="0140">It is the intent of the applicant(s) that all publications, patents and patent applications referred to in this specification are to be incorporated in their entirety by reference into the specification, as if each individual publication, patent or patent application was specifically and individually noted when referenced that it is to be incorporated herein by reference. In addition, citation or identification of any reference in this application shall not be construed as an admission that such reference is available as prior art to the present invention. To the extent that section headings are used, they should not be construed as necessarily limiting. In addition, any priority document(s) of this application is/are hereby incorporated herein by reference in its/their entirety.</p><?detailed-description description="Detailed Description" end="tail"?></description><us-claim-statement>What is claimed is:</us-claim-statement><claims id="claims"><claim id="CLM-00001" num="00001"><claim-text><b>1</b>. A composition-of-matter comprising an amorphous insulin powder soluble in water, said amorphous insulin powder including insulin attached to dextrin particles at a gm/gm ratio of 1:2500 to 1:10000 insulin to dextrin, wherein when reconstituted in deionized water at a concentration of 0.03 g amorphous insulin powder per ml water, a pH of a formed solution is 6.0-7.6.</claim-text></claim><claim id="CLM-00002" num="00002"><claim-text><b>2</b>. The composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>, further comprising sodium chloride at a gm/gm ratio of 1:100 to 1:250 sodium chloride to dextrin.</claim-text></claim><claim id="CLM-00003" num="00003"><claim-text><b>3</b>. The composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said dextrin is maltodextrin.</claim-text></claim><claim id="CLM-00004" num="00004"><claim-text><b>4</b>. The composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said dextrin is cyclodextrin.</claim-text></claim><claim id="CLM-00005" num="00005"><claim-text><b>5</b>. The composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein 1 gram of said amorphous insulin powder includes 2-40 IU of insulin.</claim-text></claim><claim id="CLM-00006" num="00006"><claim-text><b>6</b>. An infant nutrition powder comprising the composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>.</claim-text></claim><claim id="CLM-00007" num="00007"><claim-text><b>7</b>. The composition-of-matter of <claim-ref idref="CLM-00001">claim 1</claim-ref>, wherein said insulin is sequestered within cavities of said dextrin particles.</claim-text></claim><claim id="CLM-00008" num="00008"><claim-text><b>8</b>. A method of preparing an amorphous insulin powder soluble in water comprising:<claim-text>(a) solubilizing insulin in hydrochloric acid to obtain solubilized insulin;</claim-text><claim-text>(b) diluting said solubilized insulin with water and adjusting a pH to 6.9-8.0.</claim-text><claim-text>(c) adding dextrin particles to solution (b) to thereby sequester said insulin in cavities of said dextrin particles; and</claim-text><claim-text>(d) adjusting pH to 6.9-8.0.</claim-text></claim-text></claim><claim id="CLM-00009" num="00009"><claim-text><b>9</b>. The method of <claim-ref idref="CLM-00008">claim 8</claim-ref>, further comprising compounding a result of (b) or (d) with a sodium chloride solution and a maltodextrin solution at pH of 6.7-7.5 and adjusting said pH to 6.7-7.6.</claim-text></claim><claim id="CLM-00010" num="00010"><claim-text><b>10</b>. The method of <claim-ref idref="CLM-00009">claim 9</claim-ref>, further comprising filtering a result of said compounding and lyophilizing a filtrate to obtain an amorphous insulin powder with a pH 6.0-7.6 when reconstituted in deionized water at a concentration of 0.03 g amorphous insulin powder per ml water.</claim-text></claim></claims></us-patent-application>